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ABSTRACT 
Slaframine is an alkaloidal mycotoxin produced by the fungus Rhizocionia 
Icguminicola. This mycotoxin is responsible for "Blackpatch" disease on clover and other 
legumes and "Slobber" disease in livestock, Slaframine causes salivation, lacrimation. 
urination, and defecation in intoxicated animals. 
The goal of this research was to do a preliminary pharmacokinetic study on 
slaframine in lactating goats and determine if slaframine was transferred into milk. 
Slaframine was produced to dose five lactating Saanen goats at a level of 0.05 mg.'kg. 
The slaframine was delivered as an IV bolus dose. Blood, milk, and saliva samples were 
collected at timed intervals. 
All samples were analyzed by a newly developed HPLC procedure for slaframine. 
This procedure used fluorescamine derivatized slaframine to enhance detection 10-fold 
over previous GC technoicg}'. The slaframine de.nvative was found To be stable for 
several weeks. The mean recoveries of slaframine from plasma, milk, and saliva were 
95%, 91%, and 82%, respectively. 
The pharmacokinetic study indicated a two compartment model. The half-life for 
the elimination phase derived for the sample-mean of all five goats was 1.28 hours. The 
volume of distribution indicated that slaframine was highly protein-bound in goat blood. 
The mean clearance value of slaframine was 2.6 m.l/kg./h, indicating a rapid elimination of 
sisfro.r'nns rrom ths bodv 
Due to the unpredictably long half-life of slaframine in the milk, sampling duration 
was insufficient in ail but one goat to study the pharmacokinetics of slaframme m milk. 
This data would best describe the pharmacokinetic behavior as a two- or three-
compartment model. As a two-compartment model, the elimination phase of slaframine m 
milk was 23 hours. To describe the data as a three-compartment model, (with or without 
a deep compartment) iower levels of slaframine would need to be detected in plasma. 
Higher levels of slaframine were seen in milk than in plasma, which correlates well with 
the pH partition theon.'. A milk/plasma ratio of 20:1 was obtained using experimental pH 
values. 
As a result of slaframine transfer into milk, a potential hazard exists for nursing 
goats and consumers of goat milk and its by-products. Further studies are necessary for 
making risk assessments for young animals with the occurrence of slaframine in milk. 
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I. LITERATURE REVIEW 
Slaframine is an alkaloidal mycotoxin produced by the fungus Rhizoctonia 
leguminicola This mycotoxin is believed to be responsible for "Blackpatch" disease on 
clover and other legumes and "Slobber" disease in livestock. "Blackpatch" disease was 
aptly named for the dark spots of fungal growth seen on clover. "Slobber" disease was 
given its name because of the excessive salivation that occurred in animals following the 
consumption of fungal contaminated feed. 
A. Reported Histon-
"Blackpatch" was reported on red and white clover in Kentucky as early as 1933 
(1,2). In 1937, Smith (2) reported the presence of "Blackpatch" in Wisconsin. In 1947, 
Gough and Elliott (3) gave the name Rhizoctonia leguminicola to the fungus that causes 
"Blackpatch" disease. In 1950, the disease was reported in both Georgia and West 
Virginia. In Georgia, "Blackpatch" was reported on soybeans and other legumes in 
addition to clover. In 1951, Leach and Elliott (2) reported that the incidence of the 
disease varied from year to year; dependent upon the use of infected seed. 
Livestock displaying the symptoms of "Slobber" disease were observed in 
Missouri, Illinois, Indiana, and Ohio prior to 1950 (4). O'Dell (5) documented a 
slobbering problem in Missouri that continued for several years, from 1947 to 1958. The 
occurrence of the disease has also been reported in Delaware, Maryland, Pennsylvania, 
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Iowa. Tennessee, Virginia, and Nortli Carolina (4.5.6,7). 
B. Fungal Characteristics 
Rhizoaonia le^iimmicola is a pathogen that kills its host plant as it spreads (8). 
Concentric zonation occurs on the leaf in the early period of infection. The fungus then 
moves rapidly through the plant tissue, and aerial mycelia infect new^ leaf surfaces. 
Irregular lesions are formed by the overlap of necrotic areas. The fungus can overwinter 
on red clover and has been known to last for up to two years in infected seeds (4). 
The fungus does not produce spores and for this reason was not named or 
classified until 1947. The main reasons the "Blackpatch" fungus is in the genus 
Rhizoctonia cae: 1) no sporulation, 2) production of sclerotia, and 3) constriction of 
hyphae at branch points. The sclerotia of Rhizoctonia legiiminicola are either round or 
irregular in shape with rough glossy black surfaces and may not mix together to form 
clumps or irregular masses. Sclerotia have noi been obbci vcu ni uaiure but only in the 
cultured fungus when a nitrogen source is present (2). 
In pure culture, Rhizoctonia legnminicola initially appears dark green in color and 
as it gets older turns to brown and then black (2). High humidit\' is needed for aerial 
myceiia grcwxh. The paihcgen, RhizvciOr-ia leguriiinicola, appears to be ver^.' stable :n 
pure culture, and, with annual transfer of the m.old, test cultures have continued to produce 
positive tests in animals for 13 years (4,5). The dned mycelia can be viable up to 6 
months (2). Ail isolates of the fungus are known to produce the toxin (4,5). 
J 
"Blackpatch" usually develops during periods of wet weather, high humidity-, and 
miid temperatures between 25 - 29 X (4.5). The disease symptoms of the plant are 
obvious but farmers usually associate these wnh the ripening of the clover. 
In addition to red and white clover, other legumes have been infected naturally by 
the fungus Rhizoctonia Icgurninicola. These include soybean, kudzu, cowpea, blue lupine, 
alsike clover, alfalfa. Korean iespedeza, and black medic. The disease usually infests 
other legumes only when they are grown alongside red clover. Ladino clover, crimson 
clover, white sweet clover, yellow sweet clover, sour clover, and bush beans have been 
infected using artificial inoculation (4). Regardless of whether infection is natural or 
induced, no resistant varieties of clover have been found (4.5). 
Most reported cases of "Slobber" disease result from red clover hay. In addition, 
reported cases most often result from hay cut m the fall from the stubble of spring seeding 
or from second cutting hay (9). Perhaps the high moisture content of these cuttings 
contribute to tungal growtn (8). 
C. Isolation 
In the early 60's several serious outbreaks of "Slobber" disease occurred where 
carxie, horses, sheep, and goals had corisuivied forage contaminated with Rkizoaor.ia 
Icgmnir.icola. In 1962 Smalley and Crump at Wisconsin microscopically examined 
slobber forage and found the hay to be infected with a heavy dark brown mycelia. They 
identified the fungus pathogen on red clover hay as Rhizocionia Icguminicola (4.5,10,11). 
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When this fungus was produced in pure culture the mycelial mat was found to cause 
"Slobber" disease (12); Imking it directly to "Blackpatch" disease (5). 
The Wisconsin group and another in Illinois simultaneously began working on the 
isolation and purification of the slobber agent produced by Rhizocionia leguminicola The 
toxin was found to be contained in the mycelial mat and not in the culture fluid (3,13). 
The isolation and purification schem.e by the Wisconsin group is shown in Figure 1 
(11,12) and, by the Illinois group, in Figure 2 (5,13,14). 
In Wisconsin, Crump and colleagues grew Rhizoctonia leguminicola as a static 
liquid culture for 30 days on a media consisting of 100 grams of dried red clover and 100 
ml of distilled water. Later they used a defined, nine ingredient, antibiotic, test media 
developed by Gregory et al. (12). 
In Illinois, Aust grew the m.old in 300 ml Roux bottles for three weeks as a static 
culture on 20% second cutting red clover in water at 25 X. The yield per bottle was 
approximately one miHigram.,  An increase in toxin produciion was noieu when G . i - -o  
casamino acids were added to the culture. If cultures were submerged or shaken no toxin 
was produced (3). Aust later used Czapek - Dox broth with yeast extract for culture 
media (8). 
soin groups useu gumcii pijj assay dcve'opcu by O L/sil ct al. (j) to aid in the 
isolation of the toxic agent. This assay graded guinea pigs on an index of salivation 
where the following scores were given: 1- for slight salivation, 2- for intermediate 
Figure 1. Wisconsin group slaframine purification scheme. 
Rhizoaonia leguminicola cultures 
Filter 
Mycelium Culture Filtrate 
Ground in Wiley mill, add I liter 70 water 
adjust pH to 6 with HCl, stir for 2 hours 
Residue 
i 
Water 
Filtrate 
Ether 
Adjust pH to I with HCI, extract 3 x ether, 
adjust pH to 10 with Na^COj , extract 3 x CHClj 
CHCI3 layer dried to residue 
Residue 
I 
Dissolve in acidic water, extract with ether 
Water 
Add 2% Reinecke salt solution 
Water 
i-Mf C Water 
ivissoive in aceLone\waier, 
evaporate acetone 
W ater 
! A-foVo Kocir PYtrprT witVt ("'TK"'!. 
I 
Dowex 50, silicic acid, or florisil column 
Collect pooled fractions containing slafrar 
Form diaicrate salt of slafram.ine 
Fieure 2. Illinois group slaframine purification scheme. 
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Rliizocionia legumtnicola cultures 
Filter 
Mvcelium Culture Filtrate 
Homogenize with 95% ethanol 
filter through Soxhlet thimble, extract 
mycelium with ethanolic filtrate in Soxhlet 
extractor for 24 hour 
Residue Ethanol extract 
j Remove ethanol in vacuo, 
j add lead diacetate to 1% cool 4X 
centrifuge 10 min. at 16,000 g 
Residue Supemate 
Extract with CHCl3(v/v) 
discard CHCI3 , raise pH to 10 
centrifuge 10 min, at 16,000 g 
Residue Aqueous supemate 
t 1 / I -s \ hvTrpTT wnrn r-ii, u iv/v» 
Water OTT<~'1 CriLi-, 
v. 
in vacuo 
/ness 
Residue CHCL 
Dissolve in water; repeat previous 3 steps. 
Add saturated picric acid to final aqueous extract 
Slafram.ine dipicrate Supemate 
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salivation, and 3- for severe salivation (an animal graded 3- keeps the fur on the throat 
wet). Solutions of toxin were tested by interperitoneal (IP) injection. Salivation usually 
occurred within 10 - 15 minutes. If salivation had not occurred within 30 minutes the test 
was ruled negative (5,13). 
D. Purification 
The toxic principal has been extracted by either water or ethanoi and is soluble in 
chloroform but not in petroleum ether. The toxin was believed to be an alkaloid because 
of the pH effects on extraction in aqueous and alcoholic solvents. Slaframine rapidly 
hydroiyses to deacetyl slaframine at pH levels that are greater than ten. Because deacetyi 
slaframine has no slobbenng effect, care in purification must be taken to avoid this result 
(8). Upon crude purification, the toxin has given a positive Dragendorffs reaction; 
strengthening the alkaloid theory (8). Both silica and florisil columns have been used for 
iuc purificaticri of Glafrarr.ine Aiist { 'me purified ioxin the name 
slaframine from the old Norse "slafra," which means to slaver. 
The purified ioxin, as the free base, is a clear reddish colored oil (8,15). The free 
base has a molecular weight of 198. As a dry film, the free base degrades in the presence 
of air and is only stable for about two hours (8). However, slafram.ine is stable in 
chloroform or methylene chloride for several m.onths wthout solvent evaporation (8). In 
addition, while crystallization of slaframme's free base has not been possible (3,15), 
various salts of slaframine are made for stability (8). Citrate and picrate salt have been 
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the most stable of these salts in maintaining slaframme for long periods of time (8). The 
melting point for siaframine dipicrate is 183 - !84 X (3.1!). 
E. Chromatography 
Analysis techniques for slaframine include both paper and thin layer 
chromatography (8,12). Aust (11,12,16) used butanol/acetic acid/water (4/1/1, v/v/v) with 
paper chromatography,  giving an Rf of  0.25.  He visualized the result ing compound vvi th  
ninhydrin or Dragendorffs reagents. Byers and Broquist (17) obtained an Rf of 0.12 
using paper chromatography with butanol/acetic acid and Dragendorffs visualization. 
To show the presence of slaframine in hay extracts, Byers and Broquist (16) used 
normal phase thin layer chromatography developed with phenol and water; again 
visualizing with Dragendorffs reagent. Stahr (18) used normal phase thin layer 
chromatography with chloroform/methano! (80/20, v/v) and visualized the slaframine 
compouna with 5% vaniiiin in 2% suiiuric aciu. 
Analysis of siaframine by gas chromatography (GC) has been done using QY !7, 
OV 1, or SE 30 columns. Hagler (8) used a tnmethyisilyi derivative of siaframine for GC 
analysis. Stahr et ai. (19) used an acetate derivative of siaframine for GC analysis. 
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Preliminary characterization of siaframine using the ninhydrin test or the 
VanSlyke analysis revealed the presence of a primary amine group (11). Proton nuclear 
magnetic resonance (NMR) analysis indicated that a secondar\' acetate group was present. 
Further characterization by infrared spectroscopy showed that no double bonds w^ere 
present. Analysis using cyanogen bromide, which opens the nng structure, demonstrated 
the presence of a cyclic nitrogen in the ring (20). Investigations of slaframine structure by 
Aust, Broquist, and Rinehart (20,21.22) used NMR and mass spectrometry to identify the 
structure as i-acetoxy-8-aminooctahydroindolizidine. Further proton NMR investigations 
by Gardiner, Rinehart, Snyder, and Broquist (10.12.23) reassigned the structure to be IS. 
6S, 8aS-l-acetoxy-6a-aminohydroindolizine; changing the amine to the 6 position instead 
of the 8 position that had been previously assigned. 
G. Synthesis 
Slaframine has been artificially synthesized by several methods. An early attempt 
to synthesize slaframine started with 2-bromo-5-nitropyridine and utilized an 11-step 
process ^2i). Anoihcr uiciliou of slaframine syrithcs:^ utilized a 20-step process v.'ith a 
Diels-Aider cycioaddition to form the indolizidine ring (24). Two other routes to 
slaframine synthesis have started with glutamic acid. One used a 13-step process to 
produce slaframine (25). A later study used glutamic acid and obtained a 6% yield 
inrouiili i2-Sicp process (26). 
The natural synthesis route of slaframine by Rkizocionia legnminicola was 
discovered using radioacrive tracer experiments. Slaframine is formed via the hom.ocitrate 
aminoadipate pathway, where lysine is formed from acetate, alpha-ketoglutarate, and 
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glutamate in addition to carbons 2 and 3 of serine (10.12). As shown in Figure 3 (27). 
the lysine is transformed through a series of reactions to give nse to pipecolate (10,28), 
The epsilon nitrogen (not the alpha nitrogen) of lysine is incorporated into the pipecolate. 
which produces the pyridine alkaloids (29.30). Comparisons have demonstrated that using 
radioactive pipecolate is 1000 times more effective than using radioactive lysine in 
producing radioactive siaframine (27). A flavin enzyme, saccharcpine oxidase, catalyzes 
the reaction of saccharopine to A 'pipendine-6-carboxylate as one of the steps between 
lysine and pipecolate. These reactions are not seen in mam.mals but probably happen in 
plants (31). 
Pipecolate and malonate are further transformed to become siaframine (10,28). 
The direct precursor to siaframine has been shown to be deacetv'l siaframine (27). 
Among the pyridine alkaloids, siaframine is unique in that the carboxyl carbon derived 
from lysine remains in the final product (32). 
H. Saiivadon Delay 
Early feeding studies using slaframine-infected red clover hay, mycelia, or extracts 
of cultures from Rhizoctonia leguminicoia showed a delay time from oral dose to 
saiivaiion, ihe iviost apparent ciinicai response. The delay time period varied with respect 
to the t>'pe of experim.ental subjects. Delays were observed ranging from 10-30 minutes 
in experimental laboratory animals and extending up to several hours v/ith cattle (12). 
Early physiological studies used crude extracts of siaframine and, somewhat later. 
Figure 3. The biosynthesis of slaframine from lysine by Rhizoctonia iegumimcola. 
1 4  
CHNH2COOH x-^COOH^ 
NH, ~ 
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.60 
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=0 
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indolizine 
I 
t 
1-Hydroxyocta-
hydroindolizine 
(cis) 
! 
1,6-Diliydroxy-
cctahydroindolizine 
purified slaframine. Both resulted in a delay time before a response. This suggested that 
a bioactivation of slaframine was required for physiological action (3). 
Aust (8.10.1 1) systematically delayed the onset of salivation in rats by clamping 
off the portal vein and hepatic artery for varying time periods while injecting slaframine 
into via the vena cava. The more direct the route to the liver the less the time to 
salivation onset. Slaframine was shown to be most active when given via the porta! vein. 
This suggested that the liver was the major site for metabolizing slaframine and where the 
active metaboiitc could be found. This was supported by Froetsche! (8), whose 
experiments with cattle showed that the more indirect the route of slaframine to the liver, 
the longer the delay for salivation. Slaframine dosed orally results in the longest delay; 
followed, in order, fay subcutaneous (SC). interperitoneal (IP), and intervenous (IV) doses. 
The induction of liver enzymes by compounds such as phenobarbital or DDT 
significantly shortens the delay time preceding the activity of slaframine (.>,11). In 
addition, when such inducers have been used, lower doses ot toxin have elicited symptoms 
from animals (33). In direct contrast, inhibitors of liver endoplasmic reticulum (i.e. SKF 
525A, SKF 8742A. DPEA, and Lilly 18947) have all been shown to delay the onset of 
slaframine activity (5,11,34). These results provide further evidence that the activation 
of slaframine takes place in the iiver; possibly at the endoplasmic reiicuiurr. (5,i i.34;. 
The delay of salivation onset has also been correlated with the abi!it\' to 
metabolize drugs. Aust stated that goats are good xenobiotic metaboiizers and calves are 
poor xenobiotic metaboiizers (33). As a result, goats display a shoner salivation response 
than do calves. 
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L Acuvation of Slaframine 
Further experimentation involving the activation of slaframine studied both in vivo 
and in vitro activation. It was not until the activation could be done in vitro that the 
indentit>' of the active metabolite was discovered. 
The incubation of slaframine with liver microsomes and NADPH stimulated 
contraction in the guinea pig ileum.. Atropine could not reverse this. Also, using 80% 
carbon monoxide and 20% oxygen, no inhibition of the microsomal reaction that activates 
slaframine was observed. This result indicated that cytochrome P450 was not involved. 
An indication that the reaction is enzymatic resulted from the observation that boiled 
microsomes were not able to activate slaframine. Studies using microsomes suggested an 
oxidative pathway for the activation of slaframine. As a result, it is believed that a 
flavoprotein oxidase plus NADh'H pJus oxygen oxidizes siariauimc u'l tae liver (34). 
In vitro, flavinmononucieotide (FMN) with light was snowri to activate slaframine 
This resulted in a reduction of FMN at 455 nm. This knowledge was used to funher 
study the active metabolite of slaframine. It was found that the slaframine activated in 
vitro could not be extracted by organic solvcnis but could be isolated by cation exchange 
chromiatography. This resulted in the discover^' of the active metabolite. 6-ketoimine 
slaframine. This structure was confirmed by reducing the active compound of slaframine 
with deuterated sodium borohvdride. After this reaction two deuteriums were present in 
the product; one from the ketone resulting in a hydroxyl group and one from the reduction 
of the double bond in the ring structure (5.10). Similar results have been produced using 
tritiated sodium borohydride. 
The active form of slaframine (see Figure 4), the 6-ketoimine compound, resembles 
acet>'lcholine; having two adjacent carbon atoms C4 and C8a separated by a quaternary-
nitrogen atom and an ethyl ester. The charged nitrogen part of the molecule is believed to 
be involved in binding the receptor, and the 6 keto group helps stabilize the nitrogen 
atom. The rest of the molecule must be involved in specificity', such as in the exocrine 
glands. This was suggested since in experiments with prepared active metabolite no 
binding to purified nicotinic-acetylcholine receptors occurred (34). 
J. Similarities to Acetylcholine 
This conformation provides a necessary requisite for binding to muscarinic 
acet\'!choiine receptors; resuuing in ptnasy mpathomimctic action (10,31,35). Evidence 
that acuvated slaframine might have an action similar to acet\-lcholine is provided by the 
obser\'ation that atropine counteracts the effects of both the toxin and acetylcholine. Also, 
since both acetylcholine and phytostigmine cause salivation in mice, slaframine may have 
acetyicholine-like aciiO!"- {16). 
To further investigate this relationship, guinea pig ileums were assayed to measure 
responses to slaframine relative to 2cet>'ichoiine. .A decrease in response to acetylcholine 
was observed after exposure of the pig ileum to activated slafram.ir.e. In addition, a rise in 
Figure 4. The structure of slaframine and it's metabolite 6-ketoimine. 
Also, the structure of acet\'lcholine. 
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the resting level base line was seen; limiting use to five assays per pig ileum. When 
FMN-produced slaframme metabolite were used m the assay, a i 00-fold mcrease in 
response was seen relative to assays using microsomal-produced slaframme metabolite. 
The activation of slaframine in the liver is aerobic whereas the photoreduction of FMN is 
anaerobic. Deamino-slaframine reduction of FMN is also anaerobic, but no such 
biological activity is seen. (36) 
The active metabolite is very labile. Heating, raising the pH to 10, or lowering the 
pH to 2 results in a loss of activity. When using radioactive slaframine, no active 
metabolite was detected using thin layer chromatography; only slaframine and all starting 
materials were recovered. This suggested that the active species is transitory and readily 
converts back to slaframine. 
The presence of the active metabolite could be showT, by either microsom.ai or 
flavin activation. A rapid salivation response in rats was seen when an active slaframine 
metabolite produced by either FMN or flavinadeninedinucleotide (FAD) was injected. 
However, FMN was shown to be a more effective flavin than FAD (FMN was about 4 
times faster) in producing slaframine's active metaboiire. The acrive mciabuliic piodiiced 
by FMN has been observed to have an apparent half-life cf 8 minutes and decays at a first 
order rate. Similar results were obtained using microsomes. Since the half-life of the 
active species is 8 minutes, analysis must be performed within this time period. 
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The active metabolite has a somewhat unusual pharmacological action in that it 
produces a slow prolonged contraction in the ileum. This action lies between the action 
of acet\'icholine and an antichoiinesterase compound, such as eserine. Atropine, which 
reverses the effects of eserme. failed to do so when slaframine metabolite was present. 
Even with repeated washings of the ileum the contraction by the active metabolite of 
slaframine was not stopped. This result suggested a strong tight high-affinit\- binding at 
the muscarinic acetv'lcholine receptor. However, when atropine was given before 
slaframine metabolite no contraction occurred; reinforcing the similarity to cholinergic 
action. The binding of slaframine to these receptors must be greater than atropine, 
because high levels of atropine will not displace slaframine either in vitro or in vivo 
(10,34,36). 
Slaframine is a potent cholinergic compound that stimulates the exocrine glands 
(11,34). Salivation is induced by two nervous systems 1) the cholinergic 
(parasyrTipatfiomimenc) s>'srem; resulting in viscous scciciiori wiih the release of 
acetylcholine 2) the adrenergic (sympathetic) system; resulting in a v.'atery type saliva and 
the release of adrenalin. Slaframine studies in cows resulted in a viscous saliva; 
suggesting that the toxin may be acting via the cholinergic system (3). Slaframine did not 
inhibit chciinesterase (13). 
L. Review of Animai Studies 
Over the years, many physiological effects caused by slaframine have been 
reported and studied in various species. Early investigators, having witnessed field related 
effects of slaframine, began experimentation on a broad range of animals. A review of 
the animal responses to slaframine exposure foiiows; beginning with rodents and 
continuing with larger animals. 
1. Guinea Pigs 
Guinea pigs fed hay contaminated with slaframine began salivation within 48 
hours. The severity of salivation peaks at 5 days, unless the animals refuse to eat. 
Depending upon the level of slaframine contamination in the hay, guinea pig responses 
ranged from severe weight loss and death to slight weight loss and slobbering. 
Guinea pigs fed very toxic hays consumed more water and showed more 
enlargement of the lymph nodes than pigs fed hay that was only mildly toxic. Pigs fed 
highly toxic hay also showed general dehydration of tissues and abnormally small spleens 
and livers. Hemorrhage in the urinary tract and iniestine were also seen m bumc (_<ises. 
Histology showed an apparent dehydration and hyperactivity' of the saiivary glands (16). 
In general no response differences due to the sex of the pigs were noted (14). 
Crump (37) described the salivation, lacnmation, urination, and defecation (SLUD) 
effect for parasympaihomimetic responses cousisteru with the slaframine response. The 
saliva produced as a result of slaframine exposure was viscous and aerated. Lab animals 
exposed to slaframine became lethargic and have been known to develop tolerance levels. 
This mav be related to enzvme induction; where metabolite conversion and degradation 
occur at a more rapid rate (37). 
Crump et al. (8,10) reported an LD50 dose of ! mg/kg in guinea pigs. This dose 
was given oraiiy, SC, and IP. Ail pigs showed the clinical salivation response, but those 
given the IP dose died shortly after injection. Also a decrease in rectal temperature and 
respiration rate was observed in the guinea pigs (14). 
Guinea pigs given atropine along with the toxin had no symptoms after five hours. 
Pigs given atropine two hours after the toxin had severe symptoms but no death. Atropine 
given, four hours after the toxin had very little effect on relieving the symptoms of 
slaframine poisoning, but only one pig died. A guinea pig given a normally lethal dose of 
slaframine collapsed but returned to normal when given 8 mg atropine, SC. These results 
contradicted Aust's results, which showed that atropine could only block slaframine when 
administered before toxin (4). 
When guinea pigs dosed with slaframine were given methantheline bromide (a 
muscarinic antagonist^ the animals survived. When the drug was net giver., the ar.imals 
died. When hexamethonium (a nicotinic agonist) v/as given v/ith the toxin, a 2.5 hour 
delay in slaframine symptoms was seen. Lab animals given antihistamines, especially 
phenothiazine derivatives like promethazine hydrochloride (an K,-receptor antagonist), 
couid survive othsi wise leihal doses of slaframine (S.M). 
No blood cholinesterase activity changes were observed in affected guinea pigs 
relative to control pigs (14). When pigs were given lethal doses of slaframine. their 
conjunctival, oral, and other tissues were extremely pale at post mortem.. The vessels in 
the thoracic and abdominal cavities were engorged with blood. The lungs were enlarged 
and the lung surfaces were pale and dr\' and contained small hemorrhagic areas. The 
lungs also contamed a bloody foam exudate which was evident upon squeezing the tissue 
Microscopically, the lungs showed large emphysemic areas and a disrupted alveolar 
structure. Small vessels in the lungs displayed a blood deficit while larger vessels were 
observed to be engorged. Abnormal levels of eosinophils were seen in the blood, lungs, 
and submucosa. The submucosal glands of the trachea were very active and contained 
many eosinophils. Pulmonan/ edema was seen in the lower sections of the lung. The 
liver was congested and, in many areas, displayed centrilobular necrosis. The kidneys 
were also congested (4,14). However, chronic exposures of slaframiine (3 weeks) in 
guinea pigs showed no histological lesions (37). 
2. Rats and Mice 
Rats given 1 ml of crude filtrate by way of a stom.ach tube began saiivaiinu 
excessively after 90 minutes (14). Unlike guinea pigs, rats did not show clinical signs of 
lacrimation (37). 
Maseehudin and Nichols (38) conducted a slaframme study utilizing 217 rats and 
122 mice^ preparing siatramine accorcing to me meuiou oi et ai. Their doses we 
specified as a minimum salivary dose (MSD) of mat {Rhizoaonia legiimimcola) extract. 
The MSD was determined separately for each batch of mat material, because the 
impurified slaframine existed at differing levels within each mat. 
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Rats given an MSD oraiiv siiovved no ciiange in RBC, WBC, or liemoglobin, but 
neutrophils were increased three foid. Lymphocytes were depressed and clotting and 
prothrombin times were decreased. Urea, unc acid, alkaline phosphatase, and serum GOT 
levels in the blood increased. Calcium, phosphate, cholesterol, bilirubin, total protein, 
albumin, and LDH levels in the blood did not change. An oral MSD of slaframine also 
resulted in a decrease of oxygen consumption in the brain and kidney and an increase 
salivary and pancreatic activity, but no change in the liver. Gastric acidity and bile flow 
were also increased. .A.bortion. uterine hemorrhage, and death were observed in 19 dav-
old pregnant rats at a generally sublethal MSD given orally (4,38). 
As a result when 2 MSD was administered orally, heart rate, rectal temperature, 
and respiration rate were unchanged in rats. Pentobaxbital-induced sleep rimes were 
increased only when twice the MSD was given (38). 
Other investigations at varying dosages showed an increase in the contractions of 
both the uterus in mice and the colon in rats, and m.iit: iet-down in m.ice was siimuiaied 
two-fold (38). 
Aust (39) found the salivary glands and the pancreas in rats to be most susceptible 
to slaframine given at a dose of 0.6 mg/kg. The prolonged activity in these glands could 
have been due eitiier to actiVaiion cy tne iiver or to me puSbioiuly tria-t the toxiri has a 
high affinity for the receptors located there. This .may indicate the uniqueness of the 
receptors of these giands. The pancreas weight of the rats dropped to 50% that of 
controls. The amount of extractabie protein from the pancreas decreased rapidly but 
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returned to normal levels five hours after the mjection of the dose. At this time the 
pancreas weight also returned to near normal. The chymotrv'psin levels of the pancreas 
decreased to insignificant levels. A similar decrease was seen for ail digestive enz\-mes 
analyzed. This would suggest that slaframine causes the gland to secrete all the enzv-mes 
stored and then to begin synthesis of new enz>'mes. 
3. Cats 
In another study by Aust (3,5,10,12,33), an anesthetized cat was given an IV dose 
of 0.3 mg/kg slaframine. The submaxillary duct of the salivary gland was cannulated to 
measure salivary flow. Salivation was observed to begin within 30-40 minutes after the 
administration of the toxin, and continued for a six hour period. Maximum salivation 
occurred after a one-hour time period. Cats were unable to respond to a second dose of 
slaframine (1). 
All the exocrine glands, including the pancreas, were stimuiaied. and exccssivc 
lacrimation and diarrhea also occurred (1,33). But Aust (12.40) observed no effect on 
heart rate, blood pressure, ganglionic transmission, or respiration. These observations 
contradicted the work of Crump et ai. (14), Edwards and Crump (12), Maseehudin and 
Nichols (38), and Sapio and Smaiiey ^12); who aii cbssrved a decreased heart rate and 
respiration in studies involving the effects of slaframine on animals. 
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4. Chickens 
Crump et ai. (14) gave chickens 5 mi Rhizoaoma Icgnmiuicola culture filtrate. 
Salivation began after one hour, and the chickens appeared somnolent and defecated 
frequently, but recovered after several hours. 
Johnson et ai. (8) reported an LD50 for broiler chicks at 81.6 mg/kg. This high 
LD50 for chicks relative to other species suggested a difference in susceptibilit\' among 
species. This study also showed intoxicated broiler chicks to have increased nonesterified 
scids zui V2.ri2.bl6 insulin levels, 
Froetschel et al. (10) reported an LD50 of 11 mg/Tcg for 120-day-old broiler chicks. 
Perhaps age or type of chicks influence these differences in LD50 levels. Froetschel et al. 
(41) also reported that broiler chicks given slaframine at a dose of ! mg/Tcg showed a 
21.4% increase in plasma glucose after one hour. Growth hormone levels were also 
shown to increase 449% and 948% at 8 and 12 hours, respectively. Perhaps hormonal 
secretions of this type are atfectea because the endoc.nne glands die cnci vaicu by ilic 
parasympathetic neurons. 
In another study, Froetschel et al. (42) looked at slaframme's effects on digestive 
enzymes in 240-day-old broiler chicks. Separate groups of birds were fed 0, 8.9, 17.9 ug 
siairamine/kg DOGy weignt lor — i cays, ouuy wcigiit, feed intake, and cxcrcta output 
were not affected by slaframine. However, the liver weight decreased, and pancreas 
weight increased as a result of slaframine intoxication. Lipase activity decreased in chicks 
given the 17,9 ug dose. No difference was seen for other digestive enzymes, but an 
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increase in protein was seen for all birds given slaframine relative to the control 
population. 
Hagler (8) found slaframine did not effect plasma cholmesterase levels in chicks. 
This supported the theor\' that slaframine action is at the muscarinic receptor. 
5. Swine 
Crump et al. (14) also studied the effects of slaframine on swine. One pig was 
given 200 ml Rhizoaonia legnn-.inicda mat extract and another pig was given 200 ml of a 
crude filtrate (blended mat material) by stomach tube. The pig given the extract had 
excessive salivation, coughed, vomited, defecated, and urinated. Respiratory difficulties 
caused the pig to collapse. The skin was cyanotic. When this pig was given 8 mg 
atropine SC it began breathing normally and fully recovered within hours. The pig given 
the filtrate had less severe s>-mptoms and recovered without treatment. 
Swine intoxicated with slaframine in addition to a drop in respiration aiso showed 
a drop in heart rate (12). When slaframine was administered to fasted gilts no effect on 
circulating insulin was seen but there was an increase in nonesterified fatty acids relative 
to pigs in the control group (8). 
6. Horses 
While no controlled experim.ents on the effects of slaframine in horses are reported, 
field effects have beer, seen in cases where horses have consumed feed or hay containing 
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Rhizoctonia legtmiinicola. The clinical symptoms observed included excessive salivation, 
anorexia, lacrimation. diarrhea, polyuria, bloating and stiffness. In one case, abortion was 
associated with the slaframine intoxication (4,6,43 ). 
7. Ruminants 
Ruminants are the largest group of animals affected by slaframine toxicity-. This is 
due to their extensive field exposure to contaminated feedstuffs, which are the source of 
the problem. Because of this, a large number of experiments have been done on the 
effects of slaframine intoxication in ruminants. 
When a goat, a ewe, and a calf were given 0.1-0.2 mg/kg IP dose of slaframine, all 
showed an increase in pancreatic flow after a delay period (the delay was, presumably, 
caused by the necessary activation of slaframine) (3,8,12,33,35,39). In the goat and ewe 
the increased pancreatic flow lasted for several hours. The increase lasted ten hours in the 
caif (12.33). The pancreatic flow volume in the goat increased two-fold. The pruicm 
content of the pancreatic fluid increased three-foid initially but then rapidly returned to 
normal (11). 
In calves the pancreatic duct is independent of the bile duct so pancreatic fluid can 
be collected. The protein content, pH, and viscosii>' cf the paiicreatic fiuid were not 
changed significantly by slaframine intoxication (8,39). However, the .mucoprotein 
content (based on the N-acetylneuraminic acid (NANA) content) decreased approximately 
50% frcrr. norma!. There was no change in the bile now rate. 
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An increase in enzvTnatic activitv' (protein content) along with an increase in 
pancreas weight was also observed (39). in the goats an increase in the specific activity-
of tr>'psin suggested an increase in the production of digestive enzv-mes (10). In the calf 
and the goat new protein synthesis was shown by the incorporation of '""C leucine into the 
protein fraction (10.11.39). It is not known if slaframine similarly effects the secretions of 
the intestine (8). 
Crump et al. (4,14) gave steers an oral dose of a crude filtrate (blended mat 
material) of Rhizoaonia Icguminicola Salivation occurred vathin approximately 30 
minutes. Lacrimation occurred from time to time, and the salivation intensified at 24 
hours. At this time the animals ceased to eat, urinated frequently and developed waters-
diarrhea. The symptoms began to diminish at 48 hours, and the animals recovered by 96 
hours. In dairy cattle a decrease in milk production and body weight is also associated 
with slaframine toxicity. Steers given an injected slaframine dose of 18-24 (ig.^g body 
weight showed increased levels of growtn hormone, glucagon, and inulm in ilicii bloocl 
(8). 
Crump et al. (14) also gave a ewe some of the crude filtrate (blended mat material) 
by stomach tube. The ewe began salivating within one hour and developed open mouth 
breathing; becoming cyanotic. The ewe was obic; ved to be near death, was given S mg 
atropine, and recovered. No morphological tissue changes have been described in either 
sheep or cattle (4). 
The most recent work in the literature on slaframine intoxication has concentrated 
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on the potential benefits of the buffering effect that results from excessive salivation in 
ruminants. Froetschel et al. (10,44) gave rumen cannuiated wethers 0, 25, 50, or iOO 
gm/day of red clover feed pellets containing 7 ug/g slaframine. An increase in saiivarv^ 
flow ranging from 5-446% was observed. A 15-37% increase in the acetate/propionate 
ratio and a 4-18% increase in rumen dilution rate were observed. When purified 
slaframine was given SC to steers the salivary flow increased 316%. These findings 
suggest slaframine may be useful in treating digestive disorders such as feeding high grain 
ragtr-i (-'•t-1 r/M T rrVi o^rro 
Since it was established that slaframine increases salivary flow in ruminants, 
composition of saliva has been of concern. Using steers given an intermuscular (IM) dose 
at 0, 6, 12, and 24 jig slaframine,^g body weight, Froetschel et al. (45) found that salivary 
flow increased up to 68.6%. Salivary sodium content increased and potassium content 
decreased. Phosphorus concentration was unchanged, so the output of phosphorus 
increased as salivation increased. The protein content mcreased at tx^.e 12 ^g/kg dose but 
decreased at the higher dose of 24 (ig/kg. There was a decrease in the NANA 
mucoprotein constituent, probably due to dilution. There was no change in pH, 
osmolality, or buffer capacity with slaframine intoxication. Slaframine could be 
intlucncing tnc rurninsi buttering capacity onG riuic rumcvsr oy incrsssing in ssiivsr^' 
fiO vV". 
Froetschel et al. (46) also looked at the effect of slaframine on rumen motilit)'. In 
both the wethers and the steers dosed with slaframine the ruminai nressures were 
decreased. Both the primar\' and secondary contraction frequencies decreased. Inhibition 
of ruminal motilitv' has also been reported for acet>"lcho!;ne and other muscarinic agonists. 
Froetschei suggests that the release of acetv'icholine may release catecholamines; causing 
less motility by an endocrine mechanism since adrenal ectomized animals show no 
decrease in motility when given acetylcholine. Slaframine has been shown to increase 
growih hormone and glucagon levels when motility is inhibited. Gastrointestinal (GI) 
peptides and hormones have also been shown to inhibit ruminal motility. Perhaps the 
ability of slaframine to cause salivation and decrease motility indicates that different tv'pes 
of receptors are involved. Possibly slaframine affects both kinds of receptors (those in the 
GI tract and the exocrine glands), because dose level responses for each type of receptor 
have a different threshold at each site. 
Froetschei et al. (47) continued their research by using slaframine to manipulate 
the aspects of digestion such as flow, motility, and fermentation, in sheep and cattle. The 
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however, the volume and outflow both increased. These increases are probably due to the 
increase in salivation, even with the decrease in ruminal contraciions. The pH of the 
rumen increased in those animals given slaframine and the volatile fatty acids decreased. 
T 'muS rUrTiiricll l^uffcnntl mciv bs Cl rssiil* cloPromin^ Alz-mcr ImAC TQr*niiAC a] 
(48) found that ruminal now increased in sheep but not in steers. However, similar to 
Froetschei et al. (10,44), there were increases in ruminal outflow and dilution rate. .An 
increase in feed and forage intake alters the ruminal fluid balance. With the use of 
J 
siafrainine one can alter saliva levels but cannot effect feed or water intake. 
In further experiments. Froetschel et al. (49) found that saliva increased 30-40% 
and that the ruminal and abdominal outflow increased in the siaframme treated animals. 
In previous experiments it was observ^ed that slaframine did not affect the fermentation 
end products of buffering capacity. However, this could be due to the frequent feeding 
(which is knovvTi to increase pH, the acetate/propionate ratio, and ammonia in the rumen, 
and also to influence the end products) done in this experiment. There was an increase in 
post rumir.al digestion in the slaframine treated animals. Starch digestion increased with 
the level of slaframine. The microbial protein outflow was higher in the slaframine 
animals; indicating microbial efficiency. A positive correlation between salivation and 
bacterial protein synthesis resulted in animals given slaframine. and a shift in digestion 
sites from rumen to the lower digestive tract occurred. 
Kelly et al. (40) looked at slaframine as an influence on the shifting of ruminal 
digestion in cows by looking at the roie ot the reticuio-omasai orifice. The reticuio-
omasai orifice piays a .'"oie in the regulation of digestion from the rumen to the lower 
digestion tract. Slaframine increased the opening of the orifice 30-33% over controls and 
reticular contractions decreased. This agrees with the previous data on cholinergics; 
wMich show an increase in the rate of fluid and ihe paisiiyc oi paitiCLilates in the rumen. 
Slaframine prolonged the orifice opening 38% and 25%, ."-espectiveiy, for 20 and 40 ug/Kg 
body weight doses. The increase of the opening and the decrease in rumen motilit>' may 
be due to the presence of different receptor subtypes, or, possibly, slaframine could be 
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acting indirectly by releasing neuropeptides. 
Slaframine could be of assistance to animals on high-grain low-roughage diets by 
providing a more efficient mixing of saliva and rumen contents for bacterial protein 
digestion. Perhaps slaframine could assist animals on high roughage diets by increasing 
reticulo-omasal orifice opening time to move large mass material through the rumen; 
decreasing transit time and increasing intake. 
"TT^c rknfvtKiitirkn 
This research was undertaken to provide a preliminary pharmacokinetic study of 
slaframine in lactating goats. The primary goal of this work was to determine whether 
slaframiine can be transferred into milk, and, as a result move into this food source to 
nursing goats and humans. The results of this work show that slaframine is deposited into 
the milk in measurable levels. The study also investigated the rate of elimination through 
plasm.a and milk. Estimates of the half-life for the eiiminanon of slaframine from 
lactating goats were also determined. 
The study required the development of a more sensitive methodolog>' for the 
extraction and detection of slaframine in saliva, plasma, and milk. A very sensitive 
method ot detecting siairamine was aeveiopec using iiuorescaii'iiric, a fliiorcsccnt 
derivative for amines, and HPLC analysis of this derivative. 
The remainder of this dissertation outlines the work done and provides a discussion 
of the conclusions reached. Section two. Matenals and Methods, outlines the procedures 
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and methodology used in this work. The new methods developed in the course of this 
work are included in this section. Section three. Results and Discussion, provide an 
analysis of the data gathered and a discussion of the implications thereof. Section four. 
Summary, reviews the work as a whole. 
In the following discussions, all references to "water" refer to water prepared 
through a Millipore® cartridge system. All solvents used were either HPLC-grade or 
ACS reagent-grade. A listing of all supplies used and their sources is included as 
A.ppendix C. A list of abbreviations used in the text is included as Appendix D. 
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IL MATERIALS AND METHODS 
A. Growth of the Organism 
Rhizocronia leguminicola 26280 was obtained from the American Type Culture 
Collection (ATCC). Approximately 5 ml of stenle water was added to the freeze dried 
culture and mixed. The culture suspension was aseptically pippetted onto Saboraud-
dextrose (SAB-DEX) slants. The culture slants were incubated for two weeks and then 
the organism was transferred aseptically with a hooked culture wire onto new slants to 
maintain the culture. The lids of all slants were loose to allow air exchange for culture 
growth. After two weeks, slant media and growth were aseptically transferred to a 500-ml 
sterile glass blender containing 75 ml of sterile water and blended for one minute. One 
ml of this culture suspension was aseptically transferred to each of 60 SAB-DEX petri 
plates. The plates were allowed to grow for 8 days under Sylvania cool white flourescent 
tubes. Mycelial mats were collected from the petri plates and adherent agar was scraped 
from the mats. 
B. Extraction and Purification of Siaframine 
The mats were extracted in a Soxhlet apparatus for approximately 15 hours using 
800 ml of 95% ethanol. The ethanol was allowed to cool to room temperature. The 
ethariol was then divided into r.vo fractions of 400 ml and each placed in 1000-ml 
beakers. Three hundred ml of water was added to each ethanoi fraction and shaken. Tne 
-•) / 
iiH of each fraction was adjusted to 2.0 with 2N HCL. Each fraction was then extracted 
four times with 100 ml of methylene chloride each time in a 1-liter separator\- funnei. 
The resulting methylene chloride from the total of eight extractions was discarded. 
Then 200-ml saturated sodium chloride solution was added to the remaining 
aqueous portion of each of the two separatorv' funnels and mixed. Each fraction was 
placed in a lOOO-ml beaker. The pH of both fractions was adjusted to !0.0 with 10% 
sodium carbonate. These fractions were again extracted four times in 1-liter separator^' 
funnels with 100 ml of methvlene chloride for each extraction. .All m.ethvlene chloride 
(800 ml) was saved and placed into a 2-liter round-bottom flask. The methylene chloride 
was roto-evaporated at 58 X to near dryness. The residue from the flask was redissoived 
in 10 m! of HPLC-grade chloroform and transferred into a graduated tube. 
To further purify' the extract. 1 ml from the 10 ml of chloroform was streaked onto 
a 10x20 cm reverse-phase TLC plate about 2 cm in from each side edge of the plate. .A 
0.5-ug slaframine standard was spotted about 1 cm in from each side edge of the same 
plate. The reverse-phase TLC plate was developed in ethanoi/water/glacial acetic acid 
(65/35/i. v/v/v) to the top of the plate. Using a glass cutter, the TLC plate side ends were 
cut approximately 2.5 cm in from both sides of the plate. The cut parts of the TLC plate 
were placed m a TLC tank containing iodine fumes for aboui 10-15 o;* mitil 
staridards of slaframine and bands from extract are visible. The cut parts were then placed 
next to the TLC plate and the area corresponding to the slaframine standard band on the 
unexposed portion of the plate was marked using a pencil. The TLC coating in the 
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marked band was scraped from the exposed plate. This coatmg was placed in a 250-ml 
Erlenmeyer flask. This procedure was repeated for all 10 ml of chloroform extract. 
One hundred ml of HPLC-grade methanol was added to the tlask containing the 
TLC coating. The contents were mixed and the flask was placed at -lOX for 15 hours. 
The methanol mixture was then removed from the flask and placed in a 200-ml round-
bottom flask and the methanol was roto-evaporated at 58 X to dryness. The resulting 
purified film was redissolved from the round bottom flask in 10 ml of HPLC-grade 
chloroform and transferred to a graduated tube. 
Using a 10-microliter s\Tinge, one microliter was removed from the 10 ml of 
chloroform, purified extract and placed in each of three 2-dram vials. The fluorescamine 
derivatives (see section C) for each vial were prepared and analyzed to determine the 
concentration by the HPLC procedure (section D) against a known derivatized slaframine 
standard. The average of three determinations of the unknoVkTi chloroform extract was 
calculated. 
C. Preparation of the Fluorescamine Derivative for HPLC Analysis 
In all instances where fluorescamine derivatives were used, 100 microliters of a 
0.025M sodium borate - i -  O.IM HCl pH 8.5 buffer was added to a dried residue of 
standard, sample, or spiked sample and mixed v^^th a vortex mixer. Then 100 microliters 
of fluorescam.ine solution at a concentration of 6 mg/25 ml in reagent-grade acetone was 
added and vortex mixed. This mixture was concentrated to dryness by riitrogen effusion 
Willi low heat. The resulting inuorescamine derivative was used for HPLC analysis, 
D. HPLC Specifications for Fluorescamine Derivative Analysis 
A Hamilton PRP-1 reverse phase 10 }im 250 x 4.1 mm HPLC column with a 
mobile phase of acetonitrile/20mM sodium borate lOmM triethylamine pH 12.0 (35/65, 
v/v) and a flow rate of 1 ml/min was used for all HPLC analyses. A McPherson SF-749 
fluorescence detector with an HSA assembly was used with the excitation level was at the 
365 nm mercury ime and the emission used a CF 400 filter. The sensitivity range was 
set at 0.3 with a time constant of 5.0, and the suppression background set to low. The gain 
(pmt/Hv) was set at 490. The mobile phase was pumped by a Waters 6000A HPLC pump 
and a Shimadzu Sil 9A autosampler was used for injection of samples. Samples were 
injected at 10 microliters and spiked samples and standards were injected at 5 microliters. 
The readout device used was a Shimadzu CR501 Chromatopac® integrator set with an 
attenuation of 5.0 and a speed of 2 mm/min. 
E. UV Spectral Analysis 
A 20-microliter volume of the purified slaframine in chloroform (created in section 
B) was placed in a 2-dram vial. This was concentrated to dr>-ness by nitrogen effusion 
and a 200 ul of HPLC-grade methanol was added. A 20-,ul volume of the methanol 
fraction was injected into a 3x3 pecosphere C-18 HPLC column. The mobile phase was 
methanol/water {5u/5u, v. v;, at a iiow rate of 1 ml.'rriiri. and was rricmtcrcd with a Waters 
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551 diode array detector at 260 nm. The absorbance of the slaframine peak was measured 
and the concentration was calculated using Beer's Law. 
F. Preparation of the Dose 
The dosage used for the goats in this experiment was 0.05 mg/^g. The amount of 
toxin needed for the dose was measured from the chloroform concentrate which had been 
checked by using the U\' spectral analysis procedure (section E) a day prior to dosing. 
Approximately 50 minutes pnor to dosing, the measured chicroform toxin was placed in a 
50-ml beaker and concentrated to dryness by nitrogen effusion under low heat. A 0.45-
um Costar® sterile syringe filter was prewashed with 2 ml of sterile saline. Then 2 ml of 
sterile saline was added to the 50-ml beaker containing the dried slaframine. and it was 
dissolved by stirring. The prewashed filter was attached to a 5-mI synnge with needle 
and the toxin solution was poured from the beaker into the s>Tinge barrel. Using the 
syringe plunger the toxin solution was pushed through the filter and into a sterilized 
septum vial. This procedure was repeated again with another 2 ml of stenie saline 
solution to rinse the beaker and placed in the same septum vial. The vial was stored on 
ice until the dose was given. 
G. Insertion of Catheter 
The left side of the neck of the goat was first shaved to provide an unobstructed 
area for catheter insertion. The shaved area was disinfected v.nth Nolvasan® surgical 
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scrub and then with alcohol; the excess was removed with sterile gauze. A 2-cc injection 
of Procaine was then given SC to anesthetize the area. A i6-gauge needle was insened 
through the skin to provide a hole for the catheter. A 14-gauge. 5-inch angiocatheter was 
inserted through this hole and into the left jugular vein. To secure the catheter, 4 inches 
of white adhesive tape was wrapped approximately 2 cm from the top of the catheter with 
the catheter in the middle of the tape. To secure the catheter in place the tape ends were 
stitched to the goats skin. The catheter was flushed with 8 ml of sterile hepannized 
soluiion. 
H. Dosing the Animals 
The dose was removed from the sterile septum vial into a sterile syringe. The 
dose was then given into the right jugular using an 18-gauge needle attached to a 12-ml 
syringe containing the toxin dose in sterile saline. The dose was given in this manner so 
as not to interfere in the collection of blood samples. The full dose was siowiy injected 
into the goat (IV bolus). Upon complenon this was called zero time, 
I. Collection of Blood Samples 
Biood samples were taken from the first goat at zero time; zero pins 2.5, 5, 10, 15, 
30, and 45 minutes and i, i.5, 2, 3, 4, 5, 6, 7, 8, 24, and 48 hours. The remaining four 
goats were sampled on the same schedule, but only up to 5 hours. At each sampling time, 
approximately 3 m! cf blocd was removed from the catheter and discarded to eliminate 
dilution or traces of the heparin prior to blood sample collection. Two 10-ml blood 
samples were then removed from the catheter using a 18-gauge needle attached to a 12-ml 
syringe. The catheter was flushed with 8 ml of a heparm solution followmg blood 
collection to keep the catheter open. 
Each 10-ml blood sample was then placed in 10-ml EDTA vacutainer tubes. The 
EDTA tubes contaming the blood samples were immediately inverted several times to mix 
the blood with the EDTA to avoid clotting. The samples were then refrigerated. 
When the sampling period was completed for each goat, all blood samples for that 
goat were centrifuged in a clinical centrifuge for 15-30 minutes, and the plasma was 
removed. Two-m.l aliquots of plasma were placed in 10-ml test tubes (2057 Falcon), 
labeled with the goat number and the sample time, and then frozen at -10 X. 
J. Collection of Milk Samples 
Each goat was stripped of all milk immediately prior to dosing. This stripping of 
milk was identified as the zero-time sample. Milk samples were collected from, the first 
goat at zero plus 30 minutes 1. 1.5, 2, 3, 4. 5, 6. 7. 8, 24, 31.5, and 48 hours. The 
remaining goats were sam^pled at zero. 15, 30. and 45 minutes and 1. 1.5, 2, 3, 4, 5, and 
24 hours. .At each collection time the goat was totally stripped of milk to avoid the 
possible dilution of toxin transferred to the milk during the following interval. (50,5 i) 
The entire sample from each collection was immediatedly refrigerated. Upon completion 
of the collection period all milk sample volurries were ~easi:red and reccrdeci and aliqucts 
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containing 3-5 ml (wherever possible) were placed in 10-ml test tubes (2057 Falcon). The 
test tubes were labeled with the goat number and time of collection and frozen at -10 X. 
K- Collection of Saliva Samples 
Saliva samples were not taken at regular intervals because of time constraints 
resulting from other, more primary, collection activities and because of differences in 
salivation levels among the goats. Samples were collected, when possible, on 30 minute 
to 1 hour intervals. Saliva was collected manually by holding a cup under the goat's 
mouth and catching the saliva. Upon completion of the collection period, each sample's 
volume was measured and recorded along with the time of collection. Saliva was then 
measured into aliquots of 3-5 ml, transferred into 10-ml test tubes (2057 Falcon) (with the 
reserve, if any, placed in a whirl pack), and were frozen at -10 X. 
L, Method for the Extraction of Plasma 
A 1-ml volume of zero-time plasma was added to each of four separate I5-ml 
screw-cap glass test tubes. Each of these four fractions had one of the following amounts 
of slaframine added; 0, 0.05, 0.1, and 0.2 ^ig. A 1-ml volume of each timed plasma 
sample was added to a separate 15-ml screw-cap glass test tube. Ail tubes were extracted 
using the following procedure: 
Two ml of 2N HCl and 2 ml of methylene chloride were added to each test tube. 
The tubes were then vortex mixed and centrifuged at 2200 rpm for !5 minutes. The top 
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aqueous layer from each tube was then removed and placed in a 10-ml beaker. A 3-mi 
volume of IN NaOH solution was added and the pH was adjusted to 10 with 10°/o sodium 
carbonate. The contents of each iO-mi beaker was poured into a clean i5-ml screw-cap 
glass test tube. The contents of each test tube was extracted with 2 ml of methylene 
chloride and centrifuged at 2200 rpm for 15 minutes. Then this extraction was repeated. 
The bottom methylene chloride layer from both extractions was removed and 
passed through a pasteur pipette sodium sulfate column The methylene chloride extracted 
from each test tube was collected into a single 2-dram glass vial. The methylene chloride 
in each 2-dram vial was concentrated to dryness by nitrogen effusion with low heat. 
The fluorescamine derivative (see section C, above) of the slaframine for each 
extracted blood sample was prepared. A 0.1-ug slaframine standard and a fluorescamine 
blank were also prepared. Each sample was resolvated in 0.2 ml of acetonitrile/water 
(35/65, v/v). The standards and spiked samples were resolvated in 0,5 ml of 
acetonitrile/water (35/65, v/v). Samples, standards, and spiked samples were analyzed by 
KPLC (see section D). 
M. Method for the Extraction of Milk 
For each timed sample, a C-18 Sep-Pak® cartridge was prepared by forcing 4 ml 
of methanol then 4 ml of water through the canndge with a syringe. An aliquot 
containing 2 ml of milk and 2 ml of water was forced through the prepared C-18 Sep-
Pak® cartridge and the eff.uen: was discarded. A. 5-rr;! aliq'jot of water was then forced 
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through the C-18 Sep-Pak® and the effluent was discarded. Finally, 30 ml of 
methanol/water (75/25, v/v) was forced through the C-18 Sep-Pak® and the efrluent was 
collected in a 100-ml beaker. 
A 25-ml aliquot of water and a 3-ml aliquot of saturated sodium chloride solution 
were added to the beaker. The pH of this solution was adjusted to 10.0 with 10% sodium 
carbonate. The solution in the beaker was placed into a 125-ml separator\' funnel and 
extracted two times each with 10 ml of methylene chloride. 
The uiethyiene chlonde fractions v.-ere combined into a 50-m! beaker and 
concentrated to approximately 4 ml by nitrogen effusion with low heat. The concentrated 
methylene chloride was passed through a pasteur pipette sodium sulfate column and 
collected into a 2-dram vial. The beaker was rinsed with 2 ml of methylene chloride two 
times. The methylene chloride was passed again through a pasteur pipette sodium sulfate 
column and collected into a 2-dram vial. The methylene chloride in the 2-dram vial was 
evaporated to dryness under nitrogen effusion with low heat. 
The fluorescamine derivatives (see section C, above) of the extracted slaframine in 
the 2-dram vials were prepared. The samples were resolvated in 0.2 ml of 
acetonitrile/water (35/65, v/v) and the standards and spiked samples were resolvated m 0.5 
ml of acetonitrile/water (35/65, v/v). A 0.1-|ig slaframine standard and iiuorescamine 
blank were prepared with the samples. 
A standard curve was prepa-i^ed using the same C-18 Sep-Pak® procedure above 
with four 2-mI zero-time stripped mi!k samples containing 0, 0 05, 0.1, and 0.2 ug of 
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slaframine. The prepared standard curve and all milk samples were analyzed by HPLC 
(see section D). 
N. Method for the Extraction of Saliva 
Two duplicate i-ml aliquots of saliva for each collection interval were added to a 
i5-ml screw-cap glass test tubes. A 0.1-jig slaframine standard was added to one of each 
set of duplicate tubes as a spiked sample. 
To each tube, 2 ml of 2N HC! and 2 ml of methylene chloride were added, vortex 
m.ixed, and centrifuged at 2200 rpm for 15 minutes. The top aqueous layer was removed 
and placed into a 10-ml beaker. A 3-ml aliquot of IN NaOH and a 1-ml aliquot of 
saturated sodium chloride solution were added to the beaker. The pH was adjusted to 
10.0 with !0% sodium carbonate. 
The contents of each beaker was poured into a 15-ml screw-cap glass test tube. 
The contents of each test tube was extracted with 2 m! of met.'iylene chloride. The 
methylene chlonde was added, shaken by hand for 1 minute, and then centrifuged at 2200 
rpm for 15 minutes. The bottom methylene chloride layer was removed. This extraction 
was performed twice for each beaker. The combined methylene chloride from both 
extractions was passed through a pasteur pipette sodium sulfate column and coiiecied inio 
a 2-dram vial. Tne methylene chloride fractions were concentrated to dr>'ness by nitrogen 
effusion and low heat. 
The fl'jorescamine derivatives (see section C, above') were prepared for ail samoies 
and spiked samples. A O.l-ug slaframine standard and a fluorescamine blank were also 
prepared. The samples were resolvated with 0.2 mi of acetonitriie/water 135/65. v v) and 
the standards and spiked samples were resolvated with 0.5 ml of acetonitnle.'water (35,''65. 
v/v). All saliva samples were analyzed by HPLC (see section D). 
O- Statistics and Computer Analysis 
To extract the pharmacokinetic data, the PC-based program PCNONLIN 4.2 was 
used. The follov.'ing programs were used to analyze the plasma data for all five goats 
individually and for the mean of all five goats. All the models used were for IV bolus 
input. 
Model 1 is for a one compartment model. Models 7 and 8 are for two 
compartment models. Model 18 is for a three compartment model. The difference 
between models 7 and 8 is that model 7 uses microconstants as the primary parameters 
while model 8 uses macroconstants as the primary param^eters. 
Significance tests of the estimated parameters and standard errors obtained using 
PCNONLIN 4.2 were done using Student's t distribution at probability of less than 0.05 
(52). 
Sigma Plot 5.0 was used for linear regression. This program uses a laliunii! 
polynomial to compute the t values for confidence limits. Standard errors of the mean 
values were also computed using this program.. The standard deviation was calculated for 
the data from, the method evaluation by solving for sigm.a for a sample population (52). 
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IIL RESULTS AND DISCUSSION 
A. Purification of Slaframine 
Rhizocionia leguminicola was grown as described in methods section (C), and 
slaframine was purified from the culture mat material as described in methods section (D). 
The purification procedure for slaframine was modified from the Aust (5,14) and Crump 
(11,12) procedures. The culture mat material was extracted as in the Aust procedure, but 
extraction time was decreased to 15 hours. Water was added to the ethanol extract, and 
the extract was made acidic (similar to the Crump procedure), but methylene chloride was 
used to remove the fat soluble and acidic soluble impurities instead of petroleum, ether, 
(which is not as effective at removing the acidic soluble impurities). As in both 
procedures, the pH was raised to 10 for the extraction of the alkaloid, slaframine, into 
methylene chloride. In the procedure developed here, however, a saturated sodium 
chloride solution was added to enhance the recovery of the analyte. 
Further purification of slaframine was done using reverse phase thin layer 
chromatography and visualization with iodine fumes. This was based on previous work 
by this investigator (53). An example of a typical TLC plate utilized in this process is 
shown in Figure 5. The TLC coating containing the slaframine was removed after having 
been identified using the iodine visualized slaframine standards. The pure slaframine was 
elated from the reverse phase coating by soaking it in KPLC methanol as stated in 
methods section (B). The methanol was removed by roto-evaporation and the slaframine 
r-'iguro 5 .  TLC purification of slaframine 
s = 0.5 [.ig slaframine standard 
e = part of streaked slafratnine extract 
A == developed in iodine fumes 
B " undeveloped 
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was then resuspended in HPLC chloroform. Table 1 illustrates the yields of the various 
steps in this purification scheme. Only a 17% loss was seen between the first two steps. 
Overall, 40% of the pure slaframine was recovered by the TLC procedure. The 60% loss 
was probably due to poor recovery of the slaframine bound to the C-18 phase of the TLC 
coating. This procedure resulted in a knov\'n consistency and purity of the isolated 
slaframine, providing the ability to create a reproducible product. 
Table !. Punfication of slaframine from Rhizocior.ia Icgiiminicola 
Purification steps mg slaframine/60 mats % yield 
Soxhlet extraction 18.0 100 
Liquid/liquid extraction 15.0 83 
TLC purified 7.2 40 
The slaframine was stored at -10 X in HPLC chloroform for further use. This was 
done because producing the picrate for such small amounts of toxin resulted in 
unacceptable losses in the recover^' of slaframine. 
The puritv' of the slaframine was checked by UV-diode array detection. Figure 6 
shows an example of a characteristic spectrum of the pure slaframine toxin. A knowT. 
volume of the purified slaframine was chromatographed by HPLC (see methods section 
E). The slaframine eluted within 0.5 minutes and the spectrum shows one peak (at 
approximately 259 nm) denoting the purity. Using Beer's Law, the concentration of the 
Figure 6. 'I'lie UV-diode array spectra of UPLC peak of slaframiiu; fraction. 
o -p-.-
2(111 ( I  3111) Kit) 'fllO 
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slaframine was determined for the purified fractions. Aust '13) reported that slaframine 
absorbed at 260 nm with a molecular absorptivity- of 48. The concentration was then 
calculated as follows: 
= 0.0125 (absorbance units) ^ 48 (molecular absorptivitv") x 1 = mole / 1 
= 0.0002604 mole / 1 x 198 (molecular weight of slaframine) g / mole 
= 0.052 g / 1 or ug / ul X 10 (dilution factor) 
= v.5^ ug / fji in the slafrarriinc fraction 
This method of determining slaframine concentration provided good results when 
compared to a purified slaframine sample obtained as a gift from H. Broquist (Vanderbilt 
University, Nashville. TN) The concentration of the newly purified slaframine determined 
by UV-diode array methods compared favorably to the H. Broquist slaframine 
concentration when compared by gas chromatography methods, where both methods used 
acetate derivatives of the slaframine (19). The concentration from the UV-diode array 
method was also compared using the method of Stahr (54) which used a weighed quantirs' 
of purified swamsonine and quantitated slaframine by peak height comparisons of the 
acetate derivatives of swainsonine and slaframine using gas chromatography. 
B. Slaframine HPLC Analysis 
In this study the parent toxin, slaframine, was analyzed; not the active metabolite 
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of slaframine (6-ketoimine). The active metabolite has a half-life of 8 minutes. Current 
technology cannot analyze for the metabolite within the short time frame that this half-life 
provides. This was not a problem for this research, because the slaframine metabolite is 
transitory in nature and converts back to slaframine (10,51,55). 
Because relatively low levels of slaframine need to be identified in a 
pharmacokinetic study, a new and more sensitive meihodolog}" for slaframine analysis was 
developed for this research. Earlier work by this investigator using reverse-phase TLC 
showed that a fiuorescamine derivative could be made by spraying the TLC plate vrith 
base and then with fiuorescamine (56). This knowledge led to the development of a more 
sensitive HPLC method for slaframine detection. 
This method displayed several advantages. By using a fluorescent derivatizing 
agent, fiuorescamine, a 10-foId increase in sensitivity can be achieved over previous 
reported methods. Since slaframine contains a primary amine function a fiuorescamine 
derivative can easily be made. The fiuorescamine derivative is a stable derivative. 
The derivative is form.ed in a basic environment between pH 8 and pH 9. A borate 
buffer was used at pH 8.5; ensuring that the reaction would occur. The reaction occurs 
instantaneously. The extract can be dried down and stored for several weeks with no 
apparent loss. The fiuorescamine derivatized slaframine (slaframine-F) was resolvated in 
acetonitrile/water (35/65, v/v) and this, too, was stable over time, as seen in Figure 7. 
The HPLC analysis of the slaframine-F was first attempted using an Ultracarb 5 column 
' "Ol-r - .— .o«--  ^  A. \  P ] \ ;  HacicTriAn tn mv'P Hpttpr  
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Figure 7. The stabilit\' of 1 ng slaframine-F for 20 days. 
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separation and sharper peaks for basic compounds by endcapping all of the active sites. 
The column worked well for some of the preliminarv' test samples and standards with an 
acetonitrile/water (35/65, v/v) mobile phase. However, when the large number of goat 
plasma samples were run, it was discovered that the retention time (Rt) of the analyte kept 
being reduced. This reduced Rt of slaframine moved until it overlapped other peaks. The 
forward shift in Rt caused the slaframine levels to appear increasingly higher. Many 
solvent systems were tried but, due to the limited pH range of this column ( pH 2-8), were 
unsuccessful. A manual switching valve was installed to backflush the column between 
injections. This improved the situation, but it was not consistent (and it took a great deal 
of time). Therefore, it was decided that this column could not be feasibly used for this 
study. A P cyclodextrin column from Astec was tned, but it gave poor sensitivity. 
Several other columns, including the Perkin Elmer 3x3 C-18 column, were tried but gave 
poor resolution. 
The Hamilton PRP-1 C-18 column, which was rejected early in the analysis 
because it gave relatively broad peaks, was tried again. This column has a polymer C-18 
base with a pH range from 1 to 13. Various mobile phases were tried in an attempt to 
sharpen peak resolution. A mobile phase on the acid side, acetonhnle/25 mM potassium 
monophosphate 10 mM TEA pH 2 (45/55, v/v) was tried, but this eluted too many early 
compounds that interfered. The mobile phase was then switched to the basic side, 
acetonitrile/20 mM sodium borate 10 mM TEA pH 12 (35/65, v/v), which gave a baseline 
separation. At pH 12, slaframine-F was resolved from the earlier peaks. The retention 
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time of the slaframme-F m this mobile phase was approximately 7 minutes. A t>-picai 
HPLC run was 15 minutes between injection of samples, so no overlapping occurs. 
Because of the retention-time characteristics and the quality' of the peak resolution, the 
Hamilton PRP-1 column utilizing an autosampler was used for the vast number of 
analyses required for this study. 
C. Method Evaluation 
Siaframine was extracted from plasma as described in the methods section (J). The 
impurities were removed by making the plasma acidic and extracting it with methylene 
chloride. The siaframine was partitioned into the methylene chloride by first making the 
remaining aqueous extract basic at a pH. of iO. At this stage, the sample was relatively 
clean, and the siaframine was derivatized with fluorescamine for HPLC analysis. Table 2 
shows a series of ten uncontaminated plasma samples spiked at a 0.1 ppm siaframine level 
for method evaluation. The mean recoveiy- of the siaframine from plasma was 95% with a 
standard deviation of 8.! 6. 
The procedure for extracting siaframine from plasma was also tried on the milk 
samples. Unfortunately, extracting milk with methylene chloride resulted in emulsion 
problems. This caused low and variable recoveries of the siaframine from miik. 
Therefore a C-18 Sep-Pak® cartridge procedure was developed for siaframine in milk. 
The milk was passed through the Sep-Pak® cartndge; collecting the siaframine onto the 
C-iS suppon. The siaframine was eiuted with rr.ethano!'water (75,/25, v.'V). A salt 
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Table 2. Slaframine recoveries from plasma method evaluation 
(samples spiked at 0.1 ppm slaframine) 
Spiked sample % recovery-' 
1 
2 
3 
4 
5 
6 
7 
90 
104 
104 
85 
85 
103 
102 
90 
100 
""Mean recovery- is 95% with a standard deviation of 8. 
solution plus water was added to the eluted solvent. The pH of this solution was adjusted 
to 10, and the slaframine was extracted into the methylene chlonde; eliminatmg the 
emulsion problem. Table 3 shows the results of five uncontaminated milk samples spiked 
at 50 ppb slaframine. The mean recovery of slaframine from milk was 91% with a 
standard deviation of 9. 
The procedure for extraction of slafram.ine from saliva was similar to that used for 
plasma except that a saturated sodium chloride solution was added before the basic 
extraction step. The added salt forces the anaiyte into the methylene chloride fraction; 
increasing the slaframine recovery. Table 4 shows the recovenes from, ten samples of 
saiiva spiked at 0.1 ppm slaframine. The mean recover; v.-as 82% with a standard 
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Table 3. Slaframine recoveries from milk method evaluation 
(samples spiked at 0.05 ppm slaframme) 
Spiked sample % recoverv 
2 
3 
4 
5 
100 
82 
103 
83 
88 
"Mean recovery is 91% with a standard deviation of 9. 
deviation of 11. The slaframine recoveries in saliva were lower and more variable than m 
plasma or milk. Perhaps this was due to glycoproteins (mucins), which are known to be 
present in saliva (57). Slaframine being a charged molecule may be binding to these 
mucins resulting in lowered recoveries. 
D. Dosing of Goats 
In reviewTP.g the literature, no work had been done using an IV dose of slaframme 
in goats. Most previous work used oral or IP dosing of slaframine. There were only two 
reports of using goats as experimental subjects dosed with slaframine. In those 
experiments, Aust (33,39) reported IP dosing goats at a 0.1 or 0.2 mg /kg levels of 
slaframine. In spite of this, goats remained the preferred subject animals for this 
experiment, and IV dosing remained the preferred method. Goats were preferred because 
ihey are ruminants, dairy animals, and easily available; as v/ell as being of manageable 
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Tabic 4. Slaframine recoveries from saliva method evaluation 
(samples spiked at 0.1 ppm slaframme) 
Spiked sam.ple % recovery-" 
1 71 
2 77 
3 79 
4 99 
5 71 
6 73 
7 93 
8 84 
9 97 
10 7i 
"Mean recovery is 82% with a standard deviation of 11. 
size. A.n IV dosing was used to obtain pharmacokinetic parameters from slaframine blood 
level curves. Aust (33) reported the successful IV dosing of a cat at a 0.3 mg/lcg level of 
siafrarp.'.ne "w'tn fnit; informaiion^ It was dccidcu to begin the oharmacokinetic study bv 
dosing goats at a 0.3 m.g.'lcg level of slaframine. 
The first Sasjien goat, number 8909, was randomly selected from the herd The 
animal was weighed, placed in a separate pen, and provided with hay and water. The 
animal weighed 50 kg. To obtain a 0.3 mg/kg dose, 15 mg (0.3 mg/'kg x 50 kg) of 
slaframine was needed. The dose was prepared as described in methods section (F). The 
next morning the IV catheter was placed in the left jugular vein. A urinary catheter was 
inserted into the bladder (with some difficulty) and urine was drained from the bladder. 
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Milk was stripped before the dose was given. 
Goat 8909 was given an IV dose of 0.3 mg slaframine'kg body weight. Salivation 
began wTthin 2.5-5 minutes of the dosing. Blood and milk samples were taken at times 
defined in the methods sections (1 and J). Bloating of the goat was noticed at the 2-hour 
time period. The goat was removed from the stanchion several times for walks. At the 
4.5-hour time period a stomach tube was inserted to relieve the bloating. The goat died at 
the 6-hour time period. 
The goat was brought to the Iowa State University- Vetennarv' Diagnostic 
Laboratory where a post mortem was performed by Dr. Carson. No excess fluid was 
observed in the lungs. Histopathology of the lung and the liver showed congestion. The 
kidney and heart were normal by histopathology. The cause of the bloating was not clear. 
Perhaps the combined effects of eating green hay, lack of mobility, and slaframine 
influenced the death of the goat. 
The experimental plan was modified in two ways to avoid further goat monaiity. 
First, the IV dose was reduced to 0,05 mg slaframine/kg of body weight. Second, the 
animals were fasted for 15 hours prior to dosing with slaframine. 
Five goats were then randomly selected from the herd. On the day before dosing, 
subject goats were placed into separate pens and given water but no hay. On ihe day of 
dosing, the IV catheter was insened into the left jugular vein. The m:!k was stnpped 
before the dose was given to avoid dilution. No unnary catheter insertion was done as the 
previous goat, 8909, had failed tc urinate. Each of the five Saanen goats were given a 
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bolus IV dose of 0.05 mg slaframine/lcg body weight. Table 5 shows weights of the goats 
and the amount of slaframine used. The following calculation was used to determme the 
amount (in mg) of slaframine needed for each goat; 
0.05 mg X weight of goat in kg = mg of slaframine needed 
After dosing, samples of blood, milk, and saliva were collected as defined in the method 
sections ( I, j, and K). 
Table 5. Weights of goats and mg of slaframine used in pharmacokinetic study at 
0.05 mg/kg dosage level 
Goat # Weight (kg) Slaframme (mg) 
8656 72 3.6 
9106 38 1.9 
9119 50 2.5 
9122 45 2.25 
9135 38 1.9 
E. Summary of Goat Physioiogical Signs 
Salivation started within 2.5 to 5 minutes after the goats were injected wth the IV 
bolus dose of slaframine . Within about 5 to 10 minutes, the goats were observed to be 
quivering. Within 30 to 40 minutes, the goats appeared depressed and lethargic snid iheir 
ears drooped downward. Between 30 minutes and one hour, profuse salivation became a 
steady drool. The goats coughed and tried to swallow their saliva. The goats' eyes 
became gleized. and the goats staggered; appearing to be off-balance. Between 1 to 2 
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hours lacnmation occurred in some of the goats. By the 2 hour time period the sahvation 
slowed to a steady drip, but the goats still appeared depressed and lethargic. By the 3 
hour time period salivation decreased to a slow drip. At this time some goats urinated 
and/or defecated, but. in contrast to the existing literature, no diarrhea was observed. The 
goats regained an interest in drinking and eating; breaking a period of anorexia similar to 
what has commonly been reported in the existing literature. By the 4-hour time period 
salivation stopped altogether or slowed to a negligible rate. By the 5-hour time period the 
goats appeared aien and well, completely recovered. 
F. Saliva Results 
Table 6 shows the volumes of saliva collected for each goat at various time periods 
after the IV dose was given. The time periods for collecting saliva varied greatly because 
this w^as not major emphasis of the research and required the manual and time consuming 
effort of holding a container to the goats mouth. The amount of salivation was greatest 
between 2 and 4 hours after dosing (Figure 8). The large deviations reflect goat 
variability and the irregular collecting periods. All samples were analyzed by HPLC and 
compared to a duplicate spiked sample. Slaframine was not detected in any of the saliva 
samples collected from the 5 goats. The lack of slaframine in saiiva couid be due lo 
several factors; the level being far too low for detection, the slaframine being destroyed 
by freezing (this would appear to be highly unlikely), or that no siaframine entered the 
:>aii V a. 
Table o. \'o!ume (ml) of saliva collected after dosing goats with slaframine 
Goat = Time (hours) 
0.5 0.75 1.0 1.5 2.0 3.0 4.0 5.0 
8656 40.0 60.0 47.0 24.0 21.0 
9106 6.5 11.0 45.0 8.0 
9119 12.0 16.5 1.5 
9122 4.0 21.5 110.0 49.0 
9135 18.0 77.0 35.0 11.0 
G. Plasma Results 
Plasma samples were collected as stated in the methods section ( I ) and analyzed 
as described in methods section (L) for the amount of slaframine in each sample. The 
extraction of the plasma samples was duplicated, and the average of the two 
determinations for each goat are listed in Table 7. 
In the ulasma of four of the five goats no slafrarr.ir.e was found in samples taken 
beyond the three hour pomt. Slaframine in the plasma of the fourth goat, goat 8656. was 
present up to the six hour time period. This goat was four years older than all of the 
other goats and this may have affected retention time. 
A graph of the data from Table 7 is presented in Figure 9 on a semi-log scale with 
a regression line fit to the sample data means and dotted lines representing the 95% 
confidence interval around the regression. Table 8 lists the average level of slaframine in 
ppb vs. time in hours. This data is graphed in Figure 10 with a regression line and 95% 
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Figure 8. The average amount of saliva collected (ml) vs. time (hrs.) after a 0.05 
mg / kg IV dose of slaframine using five goats. 
a-Data point one goat only. 
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Table 7. Slaframine levels (ppb) m plasma samples from goats after 0.05mg/kg iV 
dose of siaframme 
Time Goat = 
(hours) 
8656^ 9106 9119 9122 9135 
0.042 24.4 11.8 24.0 64,2 
0.083 38,0 15.3 33.3 16.0 45.8 
0,166 21.5 8.3 24.0 14.0 18,7 
0.25 15.0 6.3 14.7 7.4 14,2 
0.5 9.5 3.7 8.0 5.3 9.5 
0.75 10,2 2.9 6.9 3.4 6.7 
1.0 8.6 1.7 5.9 2.2 4.1 
^ C 1 .J 7,8 1 1 3! 1.1 2,1 
2.0 6,0 0.4 2.8 0.8 1,6 
3.0 5.1 0.0 2.5 0.6 0,9 
4.0 3,7 0.0 0.0 0.0 0.0 
5.0 1.7 0.0 0.0 0.0 0,0 
6,0 2.2 
7.0 0,0 
8,0 0,0 
Ka\r/>nri 
' 'Samples were 
6,0 hours. 
analyzed to 48 hours for goat #8656. No slaframine w^as detected 
confidence intervals. Graphs are shown in Figure 11 with the same data and regression, 
but show the standard error bars instead of the confidence intervals. 
The sample data listed in Table 7 was analyzed with PCNONLIN 4.2, a 
pharmacokinetics program, as discussed in the methods section ( O ). The data was 
analyzed using one-, two-, and three-compartment models. To determine which of these 
models provided the best fit for the data, the individual data points were analyzed with 
each of the models. The output obtained from each model was then evaluated with 
respect to the correlation coefficient (y. yhat), the degrees of freedom (df), the AiC 
criteria, the standard error of the estimated parameters, and a series of graphs. 
The AIC criteria equals (-2) log (maximum likelihood) ^  2  ( ~  o f  parameters). This 
is a Bayesian mathematical analysis to predict model fitting. The lower the AIC criteria 
the better the fit (58). 
The standard errors of the estimated parameters were given a rating of good (G), 
fair (F), or poor (?) based on their ; values. Parameters that resulted in ? values with 
probabilities that were less than 0.05 were rated good. Parameters that resulted in i values 
with probabilities that were greater than 0.05 were rated poor. Parameters with / values 
falling in between these ranges were rated fair. 
A series of four graphs (identified as graphs 1 through 4) generated by each model 
were used to evaluate the fit of data to the model. Graph I. x vs. observed y and 
calculated y, was generally rated good when the majority" of predicted and observed values 
are equal or close to equal. Graph 2, observed y vs. weighted calculated y, was rated 
good when a straight line was formed. Graph 3, weighted calculated y vs. weighted 
residuals, and graph 4, x vs. the weighted residual, y, should fall close to zero (the ideal 
case) or have close to as many points above and below the zero J:ne to be rated good. 
Graphs which clearly do not meet these criteria are rated poor. Graphs v/hich fall in 
betVv 'een good and poor were rated fair. Some examples of these graphs and their ratings 
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The amount of slaframine (ppb) vs.time (hrs.) from plasma after a 0.05 
mg/kg slaframine IV dose on a semi-log scale showing data points from 
all five goats. 
Table S. Average slaframine levels (ppb) in plasma samples from five goats 
Time (hours) Slaframme (ppb) 
0.042 31.1 
0.083 29.7 
0.166 17.3 
0.25 11.5 
0.5 7.2 
0.75 6.0 
1.0 4.5 
1.5 3.0 
2.0 2.3 
3.0 1.8 
i A  
-r.Kj 0 7 
5.0 0.4 
The results of these rankings for the plasma data from each goat fitted to each of 
the three models are shown in Tables 9-12. In each of these tables, good-fair-poor 
rankings for graph 1 are replaced by actual counts of the data sample points where the 
observed y equalled the predicted y. Table 9 shows the data for each goat fitted to a one 
compartment model. Only goats 9106 and 9122 show some t~it to the one compartment 
model; having good correlation values with 10 df. fairly low AIC values, and fair-to-good 
standard errors. However, most graphs for these goats rated poor and less than half of the 
predicted values in graph 1 matched the observed values. Thus, the one-compartmen: 
model did not appear to adequately fit the observed data on the rate of slaframine 
elimination from goat plasma. 
Figure 10. The average amount of slaframine (ppb) vs. time (hrs.) from plasma after a 
0.05 mg/kg slaframine IV dose on a sem.i-log scale showing 95% 
confidence intervals. 
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Figure 11. The average amount of siaframine (ppb) vs. time (hj-s.) from plasma after a 
0.05mg/kg siaframine IV dose on a semi-log scale showing standard error 
bars. 
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Table 9. One-compartment model data summarv- for slaframine clearance using 
PCNONLIN 
Criteria Goat = 
8656 9106 9119 9122 9135 
y, yhat 0.907 0.984 0.854 0.981 0.989 
df 9 10 10 10 10 
AIC 65.17989 43.88782 72.91577 44.26696 64.66489 
Graph ! 1 2 J /4 6 
Graph 2 P P P P P 
Graph 3 P P P P P 
Graph 4 P P F P P 
Std. error F T~" r c X n VJ r. 
Table 10 shows the evaluation criteria for data fit in a three compartment model. 
Only the data from goats 9106 and 9122 could be successfully run through the 
PCNONLIN 4.2 analysis program using this model. The plasma data from the other three 
iioais resulted in an "ill conditioned program error," for the three compartment model In 
goat 9122 the correlation, df. AIC, and the first graph were all good. However, the 
majority of graphs were poor; indicating errors with respect to residuals. This probably 
accounts for the very poor standard errors of the estimated parameters in this model; some 
being upwards of 10 times the value of the actual parameters. 
Tables i i and 12 show the individual goat data run through both of the two-
compartment m.odels available in PCNONLIN 4.2. The values from both models are 
favorable for all goats with exception of goat 9119. For this goat the AIC was high, the 
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Table 10. Three-compartment model data summarv- for slaframine clearance usinsz 
PCNONLIN 
Criteria Goat = 
8656' 9106 9119^ 9122 9135" 
V, yhat 1.00 0.994 
df 6 6 
AIC -8.72663 36.38457 
Graph 1 8 8 
Graph 2 G P 
Graph 3 P P 
Graph 4 P t: 1 
ita. error P p 
"Data not suitable for estimation due to poor fit within model parameters. 
Table 11. Two-com.partment model data summary for slaframine clearance using 
PCNONLIN model 7 
i 1 ici 1 a Goat ^ 
8656 9106 9119 9122 9135 
V 0.999 1.00 0.855 0.992 0.998 
df 7 8 8 8 8 
AIC 18.51331 -10.83994 16.79713 37.02444 44.69210 
Graph 1 7 8 3 6 7 
Graph 2 G G P G G 
Graph 3 F F G ZT  ^1 r 
Graph 4 r F n. VJ G G 
Std. error G G r F G 
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Table 12. Two-compartment model data summary- for slaframme clearance usmg 
PCNONLIN model 8 
Criteria Goat = 
8656 9106 9119 9122 9135 
y, yhat 0.999 1.00 0.855 0.992 0.998 
df 7 8 8 8 8 
AIC 18.53302 -10.84033 76.77143 37,02137 44.69503 
Graph 1 7 8 3 6 7 
Graph 2 G G P G G 
Graph 3 F G G G G 
Graph 4 F G G G G 
Std. error G G r-* r C 1 G 
standard error was poor, the matching of actual and predicted values in graph 1 was low. 
and graph 2, observed y vs. weighted calculated y, did not form a straight line. For the 
other four goats, however, the best fit was obtained with the two-compartment model. 
Furihermore. a better fit "^as obtained from the tv.o-ccmpartment modei using 
macroconstants as the primary- parameters (Model 8) relative to the two-compartment 
rr.icroconstant model (Model 7). The differences between these two models was most 
apparent in the evaluation of the output graphs, as summarized in Tables 11 and 12. 
The mean value for each timed sample across all five goats (listed in Table 8) was 
analyzed using PCNONLIN 4.2, Modei 8, the two compartment model with IV bolus 
input and first order output using macroconstants as the primary parameters, where: 
C(T) = A e"' + B e'"' 
and 
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bolus IV ^ KIO 
K12 K21 
V/ 
Model 8 was used for this analysis, because P, the overall elimination rate constant, is the 
most important pharmacokinetic parameter, and it is one of the primary parameters in 
Model 8 (59). 
Table 13 shows the estimated paiamcierrs iioui i"nodeI 2 for the mean cf ail five 
goats. Looking at the a rate constants, which represent the distnbution diffusion phase 
from the central (1) to the peripheral (2) (tissue compartment), goat 9119 varied quite 
significantly from the rest of the animals. This could be responsible for the inherently 
high standard error for goat 9ii9 show, ir; Table 13. Also, the half life for the a. phase 
was the longest for goat 9119 at 22 minutes. The P half life for the elimination phase of 
slaframine shows a variance from 25 minutes to 2.25 hours w.th a mean of 1.28 houi's. 
The eliminati.on phase of slaframine in goats 9106, 9135, and 9122 was very short ranging 
/ / 
l abie 13. Estimated parameters from piasma data using PCNONLIN modei 8 
Parameters Goat = 
8656 9106 9iI9 9122 9135 Mean 
68.920420 35.053434 22.370246 20.92704 90.405224 33.847595 
(4.621549) (0.895421) (27.163673) (4.134611) (5.474531) (2.924315) 
17.898215 1 .879270 12.407924 
(0.777168) (3.045749) (6.439807) 
8.371511 2.830716 
(0.386537) (29.267920) 
0.313183 1.502172 0.308044 1.626413 1.059072 0.539733 
(0.032881) (0.082925) (3.274642) (0.626643) (0.361336) (0.260393) 
0.060039 0.038727 0.368838 0.055863 0.053084 0.103227 
(0.004185) (0.001680) (0.597183) (0.028964) (0.007108) (0.019954) 
0.461430 2.250156 
(0.025447) (23.896250) 
7.531426 21.093012 
'0 16! 1'^8* '-^0 
A [ng/ml] 
cx [h-'j 
B [ng/ml] 
(3 ri 
t, : r .  [h-'] 
AUC 
I IT ' T-v-1 I ' H I 
r\ 
[ml/Kg/hj 
MRT [h] 
Vd 
[ml/kg] 
11.544948 
(0.805527) 
11.914159 
(0.617016) 
2.213232 
(0.232135) 
44.011880 
( "> 7 J I Ut it l * 
1 136057 
(0.070879) 
2.771668 
(0.306959) 
3 6 
6.638849 
I r\ 1 « ^ 1 \ 
[ v .  / 1 )  
0.507121 
(0.026914) 
4.4 
2.370453 
(4.521102) 
1.714569 
(14.468242) 
7.7 
11.731859 
(4.750630) 
0.42618! 
(0.164040) 
8.899570 
(I 1 ^ R 1 a ^  ^  
5.618249 
/ A 1 \ (0. / 1 ; 
0.513622 
(0.162595) 
3.5 
13.057667 
(1.750109) 
13.582750 
(3.745858) 
0.654485 
(0.223075) 
19.748680 
I 2 270073") 
2.531815 
(A lO I 't QO \ 1 -rO^ / 
0.640044 
(0.215127) 
2.4 
6.714806 
(1.299314) 
7.514404 
(2.591182) 
1.284242 
(0.618962) 
18.963199 
i"> 79723v'i 
2.636686 
(0.528849) 
1.399859 
(0.672889) 
4.9 
Parenthesis denote standard errors of the parameters. 
from 25 to 59 minutes: however, the eiimmation phase of slaframine m goats 8656 and 
9i 19 was longer at approximately 2.2 hours. This could be due to variation of the rate of 
metabolism within in the species. 
The volume of distribution (Vd), the sum of volumes of the centra! and peripheral 
distribution compartments, can be calculated from the data in Table 13 using the following 
formula (59); 
dose Va = 
. A T T/-t\ , 0 \ 
While experiments on the protein binding of slaframine have not been done, low Vd 
values indicate that xenobiotics are highly protein-bound in blood (59). The Vd value for 
slaframine was 4.9 ml/rcg, which suggests it is highly protein-bound in goat's blood. 
Body clearance ( C I J  is a measure of the ability of a substance to be removed by 
the organs of elimination (the sum of all clearance processes in the body) (59). From 
Table !3 we can see that the mean clearance value for slaframine was 2.6 ml.'kg/h. This 
indicates a rapid elimination. 
H. Milk Results 
Milk sam.ples were collected as stated in the methods section ( j). Table 14 shows 
the volumes of milk collected after dosing the goats with slaframine. The average amount 
ui liiiixs. cuiiCciCu ai v-v/ilCCiiOu uinv li) uicipiiwwi n* ^ ^ ... 
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this experiment were near the end of their lactation stage, and this may have contributed 
to the lack of milk from goat 9122. Slaframine may also shut down milk production in 
the lactating goats. Slaframine is knowTi to depress milk production; as reported in the 
literature by Aust et al.. (11) and Crump et al. (60). Contnbuting to this loss of milk 
production was the loss of fluid by 1) the increase of salivation and 2) the depression of 
the animal, which resulted in a lack of water intake. Thus, with the loss of fiuid from the 
goat and lack of replenishing fluid to the goat, milk production suffers with a decrease in 
Table 14. Volume (ml) of milk collected after dosing goats with slaframine 
Time Goat U 
(hours) 
8656 9106 9119 9122 9135 
0.0 60.0 122.0 740.0 332.0 164.0 
0.25 29.0 68.0 45.0 25.0 
0.5 17.0 12.0 17.0 4.0 10.0 
0 75 7  C  1 0 
1.0 49.0 2.5 2.5 0.5 ] .5 
1.5 29.0 4.5 1.5 0.4 2.5 
O  A  
^.\J 15.0 I  5  1.7 0.0 1.2 
3 0 7.5 4.5 1.5 0.0 1.5 
4.0 19.0 3.5 0.0 0.0 1.5 
5.0 32.0 2.5 0.5 r\ r\ u . u  1.0 
6.0 9.0 
7.0 6.0 
8.0 13.0 
24.0 575.0 62.0 5.0 A  - i . U  10.5 
31.5 400.0 
48.0 945.0 
80 
Time (hours)  
Figure 12. The average amount of milk collected (mi) vs. time (hrs.) after an IV 
dose of 0.05 mg/lcg slaframine. 
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output. Whether slaframine is affecting milk production at the hormonal level is not 
known. 
Table 15 shows the level of slaframine detected in each of the milk samples taken. 
Slaframine was found to be transferred into the milk and was seen in the earliest samples 
taken (zerotime plus fifteen minutes). Figure 13 illustrates this graphically by showing the 
average amount of slaframine transferred into the milk over time. It was expected that 
slaframine levels in the milk would initially increase during an absorption phase and then 
would steadily decrease as a result of the repeated stripping of milk from, the udder (6!). 
Table 15. Slaframine levels (ppb) in milk samples from goats after O.OSmg/'kg IV dose 
of slaframine 
Time Goat # 
(hours) 
8656 9106 9119 9122 9135 
A 0.66 3.2 3.5 0.47 
0.5 15.9 0.72 3.7 2.4 U.77 
0.75 4.7 3.9 
1.0 19.0 2.1 5.7 7.6 7.2 
1.5 17.5 1.7 9.0 9.5 2.0 
2.0 14.1 2.8 8.6 1.1 
3.0 •4.*4 1.0 9.1 0.4 
4.0 9.4 1.3 0.35 
5.0 4.9 1.1 15.1 0.0 
6.0 5.2 
7.0 •-» 7 -1. i 
8.0 2.3 
24.0 2.0 0.9 7.7 25.9 0,8 
31.5 4.0 
48.0 1.5 
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Figure 13. The average amount of slaframme (ppb) vs time (hrs.) transferred into milk 
from a 0.05 mg / kg IV dose of slaframine usmg five goats. 
a-Data points from goat 8656 only. 
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The levels of slaframine seem to increase, fall off increase, and fall off again 
during the first eight-hour period. Perhaps this could be release from some other 
peripheral tissue (a deep compartment). Between the stnppings at 8 and 24 hours the 
slaframine levels increased a second time. This, again, might be due to a peripheral 
release, or it might be due to slaframine concentration in the milk over this first extended 
(over 1 hour) time period between milk stnppings. The table in Appendix B shows the 
total amount of slaframine in milk along with the dose given to each goat. The goats 
were given milligram levels but microgram level of slaframine was seen in the milk, a 
factor of 1000 difference. 
Milk samples were collected to the 48 hour time period for only the first animal, 
goat 8656. For the remaining goats milk samples were collected only up to the 24 hour 
time period. This change was made because slaframine levels in the plasma samples 
(which were analyzed immediately) of goat 8656 were observed to be zero after 6 hours. 
This led to the assumption that slaxVamine would be eiim.inaied fro.m the miik wuhm 24 
hours of dosing. In retrospect, the analysis of miik samples (which were done as a group 
after all goats had been dosed and sampled) indicated that slaframine was still present m 
the milk of goat 8656 at the 48 hour sampling period. A longer sampling time period 
would be needed to lUliy understand the eiiminaiior. of slariaiVi-ric from the milk. 
Due to the truncated sample data, it was difficult to utilize the m.iik data in a 
pharmacokinetic model. A preliminary estimation of the model could be approximated by 
using the data from goat 8656. In a one-comoanment model, drugs or toxins in milk have 
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only one elimination constant. However, in a two- or a three-compartment model, the 
drug or toxin that is eliminated into the milk compartment can diffuse back to the central 
compartment (unlike the situation that exists in the case of unnarv- excretion). As a result 
of this complication, another elimination constant (a K20 in a two compartment m.odel or 
a K30 in a three compartment model) must also be interpreted (62). This results in what 
is referred to as a diffusion model. The diffusion model takes into account the protein-
bound and the unbound toxin with the unionized toxin migration in both directions across 
the mammarv' membrane (61,63,64). 
None of the models supplied by PCNONLIN 4.2 incorporates secondary 
elimination, so using the program for this analysis was not feasible. However, it was 
possible to use the milk-to-plasma ratio (M/P) and to compare the result obtained here to 
the resultant graphs for one-, two-, or three-compartment models based on Wilson et al. 
(62). Figure 14 shows the M/P vs. time for goat 8656. Appendix C shows Wilson's M/P 
vs. time graphs for one-, iwo-, and iliicc-t-orupartment models. A ccrr.par:scn :n±cated 
that a two-compartment or a three-compartment model was most consistent with the milk 
data collected from goat 8656. 
Figure 15 shows slaframine levels in milk and plasma samples from goat 8656 
graphed vs. time on a serrii-log scale. The data from milk parallels the plasma quite well 
given the obser/ation that the m.iik contains a higher level of slaframine. This can be 
explained by the pH partition theorv' using the Henderson-Hasselbalch equation (65) for 
basic molecules: 
8 5  
Figure 14. Milk / Plasma (M/P) ratio vs. time (hrs.) from goat 8656 after a 0.05 rng'^kg 
iV dose of siaframine. 
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Figure 15. Slaframine (ppb) vs. time (hrs.) from goat 8656 in milk and plasm.a 
after a 0.05 mg.'Qtg IV dose of slaframine on a semi-log scale. 
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, unionized . U pH-pka =log——:—— = log— 
lonizi^ci 1 
Where: slaframine pKa = 9.1 (66) 
plasma pH = 8.0 (obtained experimentally) 
milk pH = 6.7 (obtained experimentaily). 
in plasma for goat 8656; 
8.0-9.1 = iog-y 
If U=l, then; 
11 1 u 
-1.1 = logy 
0.08 = -
I 
0.08 = -
^ -  i n  
0.08 
U + I  =  1 3 . 5  
In milk for goat 8656; 
8 8  
6.7-9.1 = log^ 
T 
-2.4 = logy 
O.CKM = — 
If U=l, then: 
0.004 = -
I 
I = —^ = 250 
0.004 
U + I  =  2 5 1  
Thus, the ratio be^.vee^ the piasma and the milk was determined to be approximately 1 to 
20. The diffusion gradient favors the milk side so higher levels of slaframine are 
deposited into the milk as shown in figure 15. 
Experiments using centrifugation ultraflitrate devices were tried on a few plasma 
and milk samples to look at the protein-bound vs. the unbound toxin. But difficulty in 
reproducible spike recoveries and the total clogging of the m.embrane with the milk 
sam.ples made this work unfeasible. Figure 16 shows milk data from goat 8656 
(slafram.ine vs. time) on a semi-logarithmic scale. 3y using the slope (beta) of the lower 
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Figure 16. The average amount of slaframine (ppb) vs. time (hrs.) transferred into milk 
from 0.05 mg / kg IV dose of slaframine on a semi-log scale for goat 
8656. 
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line of the elimination phase, we can calculate a rough estimate of the t, -of the 
slaframine in milk usinsz the formula: 
0.693 
V-- p 
0.693 , t,n = = 23 hoiirs 1/2 A na 
There exists a significant potential for error in this estimation as a result of using 
one animal at one dose level. The half life for milk should be equal to the half life of 
plasma. Several reasons may exist for the relatively long half life in the milk when 
compared to the plasma. Either the analytical method needs to be more sensitive in order 
to detect lower levels of slaframine in the plasma (a possibility in a three-compartment 
model), or a deep pharmacokinetic compartment may exist which may result in a later 
release of slaframine. The diffusion gradient contributes to both theories. 
L Suggested Future Experiments 
While this research has conclusively shown that slaframine was transferred into 
milk, many questions have been ieft unanswered as a result of this research. Future 
experiments can help delineate some of these questions. 
The bioavailabilitv of slaframine in the milk can be determined if the AuC in milk 
is calculated. Then the percentage of the slaframine dose that is transferred to the milk 
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can be determined. The toxic risk remains unknown for the young goats, since slaframine 
must be metabolized into the 6-ketoimine to be activated. There is currently no data on 
how well slaframine is metabolized by young goats. There is also a potential risk that 
slaframine can enter the human food chain through dairy products. However, the stabilit>' 
of slaframine through the dairv- processing system is also unknovvn. The potential exists 
for more experimental work to further define and quantify each of these risks, since the 
methodology for identifying and quantifying the presence of slaframine in milk now 
exists. 
More research could further investigate elimination rates of slaframine in goats. 
Other IV dosing levels of slaframine should be tried to determine if the rate of elimination 
is dose dependent. A repeat of the current study's 0.05 mg/Tcg IV dose level of slaframine 
should be done v^-ith milk samples taken for a longer period of time (out to 2 or 3 half-
lifes) to more accurately track the final elimination of slaframine from the milk. Also 
other routes of excretion, such as urine and feces, could be investigated. 
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W. SI M.\1\RV 
This research was uridertaken to provide a preliminarv- study of the 
pharmacokinetics of slaframine m lactating goats. Particularly, it was designed to see if 
slaframine was transferred into milk. While substantial previous work had been done on 
the effects of slaframine intoxication on various species, no previous investigation has 
directly addressed the movement of slaframine through the body. 
To complete this study a more sensitive method for slaframine analysis has been 
developed utilizing fiuorescamine (fluorescent derivatizing agent) and HPLC. Methods for 
the extraction of slaframine from plasma, milk, and saliva have been developed. The 
method developed utilizing the fiuorescamine derivatized slaframine gave a ten fold 
increase in detection levels over the previous GC technology. The slaframine 
fiuorescamine derivative was stable for several weeks; allowing storage of samples 
between extraction and analysis time. The plasma and saliva procedures used a 
liquid/liquid partition between an acid'base parrition into methylene chloride. The mean 
recovery for plasma using the methods developed was 95% with a standard deviation of 8 
and, for saliva, was 82% with a standard deviation of 11. The milk procedure used a C-
18 Sep-Pak® cartridge clean-up with a mean recovery of 91% with a standard deviation 
of 9. 
The pharmacokinetic study of slaframine in lactating goats was initiated with an IV 
bolus dose of 0.05 m.g slaframine/kg body weight. Analysis of the piasma data indicated 
v3 
a two compartment model. The mean half-life for the elimmation rate of slaframme was 
1.28 hours. The Vd values indicated that siaframine was highly protein-bound in the goat 
blood. The CL for siaframine at this dose was rapid with a mean value of 2.6 ml/Kg.'h. 
The preliminarv milk data from goat 8656 indicated a two or three compartment model. 
With a two compartment model a deep compartment may also exist due to the half-life for 
the elimination of siaframine in milk being 23 hours. A three compartment model could 
possibly be the case (with or without a deep compartment), but confirmation of this case 
would require that lov/er levels of siaframine in plasma would need to be detected. A 
higher level of siaframine was seen in milk than in plasma. This is consistent with the pH 
partition theory that indicates a theoretical M/P ratio of 20; 1; using experimentally 
determined pH values for milk and plasma. When milligram levels of siaframine were 
given microgram level of siaframine was transferred into milk, a factor of 1000 difference. 
Due to the abi!it\' of siaframine to be transported into milk a potential hazard exists 
for young nursing goats. More experimental work is needed m ilns, mcd io uelernnne the 
percentage of siaframine available to the young goat dependent on the mother's dose level 
and how young goats metabolize siaframine. 
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APPENDIX A 
EXAMPLE GKAPHS FOR MODEL EVALUATION 
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Graphs rated fair; 
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APPENDIX B 
TOTAL AMOUNT OF SLAFRAMINE IN MILK AFTER DOSE 
1 ime Goat = 
(hours) 
8656 9106 9119 9122 9135 
0 0 0 0 A yj 0 
0.25 19.1 217.6 157.5 11.8 
0.5 270 8.6 62.9 9.6 7.7 
0.75 16.5 3.9 
1.0 931 5.3 14.3 3.8 10.8 
1.5 507.5 7.7 10.5 3.8 5.0 
2.0 2n.5 4.2 14.6 1.3 
3.0 33 4.5 13.7 0.6 
4.0 178.6 3.9 0.5 
5.0 156.8 7.6 
6.0 46.8 
7.0 10.5 
8.0 29.9 
24.0 1150 55.8 38.5 51.8 8.4 
31.5 1600 
0 1 -1 T r ! H 1 / J 
S!aframine(ng) 
in milk 6543.1 109.1 396.2 230.4 46.1 
Slaframine(mg) 
dose eiven 3.6 i.9 2.5 2.25 L9 
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APPENDIX C 
GIL^PHS FOR MILK/PLAS\LA. RATIO MODELS 
One ComDSTtment Model 
c 2-
c. 
3 T-
Two CompartnieiiL Model 
Three Ccin.i!2rt!iieiit Model 
< -I  
O 
cz 
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APPENDLX D 
SUPPLY VENDORS FOR MATERIALS 
American Type Culture Collection 
Rockville, MD 
26280 Rhi-ocionia leguminicola freeze dried culture 
Becton Dickenson 
Sandy, UT 
14 gauge, 5 inch angiocatheter 
Central Stores, Iowa State University' 
Ames, lA 
Sylvania coo! white bulbs 
College of Veterinary Medicine clinic pharmacy, Iowa State University 
A.mes, lA 
sterile heparin solution 10 units/ml 
CoStar 
Cambridge, MA 
0.45 um sterile filter 
L'2!r\' 'nw3 Siaie limversiiv 
Ames, lA 
5 - Saanen lactating does (goats) 
Scjetij"*c Cc. 
Chicago, IL 
soxhiet apparatus 
methylene chloride 
sodium chloride 
sodium carbonate 
1 liter, 125, 250 m! separator,' funnels 
Buchii Roto Evaporator 
glacial acetic acid 
HPLC grade methanol 
HPLC grade chloroform 
5, 10, 50, iOO, iOGO mi beakers 
1 1 0  
10-20 ml septum vial 
EDTA 10 ml vacutainer blood collection tubes 
Falcon 2057 snap cap test tubes 
ACS grade HCL 
ACS grade sodium hydroxide 
sodium sulfate 
HPLC grade acetonitrile 
TLC tank 
250 mi erlenmeyer flask 
pasteur pippettes 
Optima grade acetone 
sodium borate 
Genie 2 vortex mixer 
15 ml screw cap glass test tubes 
Hamilton 
Reno, NV 
PRP-1 10 fim 250 X 4.1 mm HPLC column 
10 microliter syrmge 
lEC International Centrifuge 
Needham Hts., MA 
clinical centrifuge 
centrifuge 
J T" Ti -aL-or 
Phillipsburg, NJ 
iodine crystals 
McPherson, Division of S.L Corp. 
Acton, MA 
rL-749 HPLC fluorescence detector with HS.A. assembly 
Midland Scientific Inc. 
Omaha, NE 
500 ml glass blender 
Midwest Grain Products Co. 
Weston, MO 
95% ethanol 
I l l  
Millipore Corp. 
Marlborough. MA 
millipore Q water 
Millipore - Waters Chromatography Division 
Marlborough, MA 
990 Diode Array detector 
6000A HPLC pump 
C-18 Sep-Paks® 
Parkin Elmer Corp. 
Norwalk, CT 
3x3C pecoshere cartridge C-18 HPLC column 
Rochester Scientific 
Rochester, NY 
2 dram glass vials 
Statictical Consultants, Inc. 
Lexington, KY 
PCNONLIN 4.2 
Sherwood Medical Inc. 
St. Louis, MO 
5, 12 ml monoject syringes 
'6 yaijye 1.5 ificii iuonoicCt uccdlcs 
Sigma Chemical Co. 
St. Louis, MO 
fl 1 3 
tri ethyl amine 
Shimadzu 
Columbia. MD 
Sil 9 HPLC autosampler 
CR 50! integrator 
VWR Scientific 
Ontario, Canada 
standard 100 x 15 mm. sterile disposable petn plates 
1 1 2  
Whatman Inc. 
Clifton. NJ 
reverse phase C-18 TLC plates 
1 1 3  
APPENDIX E 
LIST OF ABBREVIATIONS 
ATCC - American Type Culture Collection 
A - Intercept of monoexponential absorption slope with ordinate 
AUC - Area under the curve. 
a - alpha 
B - Intercept of back-extrapolated monoexponential elimination slope with ordinate 
P - Beta 
oC - degrees Celsius 
C-18 - Carbon chain of 18 units 
'"C - Carbon 14 
CI;, - Body clearance 
C(T) - Blood concentration at time T 
Qi" - Gcgicci K J l  i i c c u u m  
FAD - Flavin adenine dinucieotide 
PMN - Flavin mononucleotide 
^ - ^raiu 
GC - gas chromatography 
GI - Gastrointestinal 
1  14  
GOT - Glutamic oxaloacetic transaminase 
h - hour 
HCl - Hydrochloric acid 
HPLC - High pressure liquid chromatography 
I - Ionized 
IM - Intermuscular 
IP - Interperitoneal 
IV - Intervenous 
K I O  -  O v e r a l l  e l i m i n a t i o n  r a t e  c o n s t a n t  
K12 - Distribution rate constant for transfer from central to peripheral compartment 
K21 - Distribution rate constant for transfer from peripheral to central compartment 
kg - kilogram 
1 - liter 
LDH - Lactate dehydrogenase 
mg - milligram 
ml - milliter 
mM - millimolar 
M/P - Milk to plasma ratio 
MSD - Minimum salivary dose 
N - Normality 
NAE)rn - iNicoiine acenine Qipnosphatc 
1 1 5  
NANA - N-acetv'lneuraminic acid 
nm - Nanometer 
NMR - Nuclear magnetic resonance 
NaOH - Sodium hydroxide 
PC - personal computer 
pH - Measure of hydrogen ion concentration 
pKa - Measurement where the ratio of unionized and ionized species are equal (half-way 
titration point) 
ppb - Parts per billion 
ppm - Parts per million 
® - Registered trademark 
RBC - Red blood cell 
Rf - Reference value 
_ P 0-* roi iitic miniiT^s 
Rt - Retention time 
D O - n , y v  -  o a u o j a u u  u C A . t i c ; i > w  m s - s a i a  
SC - Subcutaneous 
SD - Standard deviation 
Slaframine-F - Fluorescamine denvatized slaframine 
t - time 
t , ,  -  H a l f - l i f e  
TEA - Triethylamine 
TLC - Thin layer chromatograph 
U - Unionized 
ug - microgram 
|il - microliter 
|jm - micrometer 
UV - Ultraviolet 
V - volum.e 
Vd - Volume of distribution 
vs. - verses 
WBC - White blood cell 
A - delta 
% - percent 
